var title_f1_32_1536="Newborn clavicle fracture";
var content_f1_32_1536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Newborn with left mid clavicle fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rajvee Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1536=[""].join("\n");
var outline_f1_32_1536=null;
var title_f1_32_1537="Night splint PI";
var content_f1_32_1537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Night splint to treat a bunion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 364px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFsAfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5pRsGrUUmRVQinI2K6U7HO1cu8EdKNgPamxPnrUw6VpuZPQj8vnineXipOhpQelOwrkTDA4FIDyO1SsM9qjKkUgTHqM07BHSo1OKkHPFMTEDetWYX96i8vihRg800S9S4Dnnr6Uxl4OaIzkU89OlWZ7FSSMDtVY/K3NaRAP1qtLHzUNGkZEScgVKp9/pUK/KakXrQhsl/nTCPTtSgH/Cgj2Of5UyRqHaav203QZqmyZpFJQ0J2Bq5tAggnI+tOWqFvP05rQiYN6cdK1Tuc8lYcOnFNKE1IBzUgUEc0yLkAXH0p3cDH51I6hcEUKvzc4zQFxoTPQUBcNg1OBx2pGX/APVTFciC5OPwpyr6dqXtxmnDpx1oAMY6HFL1xSD6daevAz+VAhQv0pGHBPb3oLc0oGce9AiMjHXNKrfMPSpWUnioWXaeBQNE64b601wR9KI+lPwD1oERZHpxT07UgU5qRB3xgUAxcfLwOKryrmrBIGfXtUZAzTBFQrx0oFTMvXA5qMrzzU2KuRMcdaXPtS7ST0qWOLp/hQNsjGT60qrzzipxF/8AWpGXA4oFcaF7dRT8EYGMDvTOc1IM56cUxMacimscdae2fxpuM9qAQ0Up4HSlxj60h9MdaQEbn8qhNTMo61GV5oKQ3pk01uetSgHFMI6AUhjDyPQ01hzzwafjpzTCMUMaEODRS455FFAzjQtG2ngcU7Fclj0rjUOKtRtuFVSMcipI2GaadiWrlqlNNQginAZ4qzMMnODTtoxz1pVUY4p4GaZNyErzT4+ozUuzINRNkUWsF7lhRmgr3pkT569asAD8apakPQYgwcmpeuOQM0wDHNSAdM96aJY0KeeKSSPK9KmA/KpFXIFOwuYyniw3SkTqM1oyw5BwKpSR7T06VDVjRSuKuPWnd+n4VEpwealU5HNCBigfSmsv1qRRx70Ef/rp2FciQlTV+1lqg4xUkEm00J2FJXRtodwqUcLiqNvKDV1OenNao5mrCsOPegdeBzSnOTTSSTQJDw3NPyP89qiH0p1MQv8AKjjvSg8Z5pje1ADhyRjrStjHIwBTQeppAaAHAflU6gU2P07U7B7H9KBMXHHrUbrUq59aHHTjj1oFcgBIPSrA5GelQEYOQKkTg+9A2P7+9I3Hr+FP6ConOTgHNAhrNz65oHahRk/4VLs9s0DISOOOlJ5efpVjaB2p4Axz0oFcqBMSAYOT37CplA708kdvzppPGaAEY546VC4NTHnHpSOvHFAIq4OT6dqkU8UjqBn9aQDp/nFBQp5HpSg+tBzj9aRfegQ5uevam9c+o4pefSk5oAbjikKjinfWk3Hd0yMZzQMaQAO+KjOAcmpDzyTxTD9OKQ0MI46Uzbzn09akI4pB0xSKuRlf84op7dBwfwooGcQD7U8U0oc0AEVyHp7kgBxSEYPAoVqdnOSKZJJE3NWF6cVUQ4NWozVIiSJAenXFPU9/ShVFPxVGbJFGaZKme2DSg8Cn/eHWqJ2KmCrZqeNwRzSvHnkVCQQRilsVuW+vp9KlQfnVaJ/U1bUZqlqZPQQDHQfjT09KNp7c0oBqiSQDK4qGeDI47VOhwKfjIFO1yb2MWSMg5FCZNaFxDn61SljKms2rGylcVakWq+4g9Kmjbn1oQNA6Z571DtINXcBh2zUbpim0JSI4ZCpzmtO1m49qyiv+FSQOUI9KE7BKN0dAuGXtQV46Yqjb3AJq+jhx2rS9zmaaGgd+lL3znGafimE7c+tMW4hOD1pAcdDTC3PNKpwOlIdhxP60qDOPSmdccc1MgwSKYiReAKcD+VRk4FIGAOc8UCsTgD8/anEDnv71GjZ4qZaZLIWTPsKVRTzgA8cU0cmkMRjnihY+elSKvrUijFAXGogGOlKw9KcSBTG5HFMQ1ifSkJGBgUmDxS9vc9aQxjHkemOfWmscA5/KnEAfSmE88d6Bi7sE85p2Qe9QYOQacrAE+vpQFgk69PamgYOOn0pxOecZFN6H2oADyeKAOxzS57ml6YxwaAA4+lJgfSmscZxyKQnjp+NACE/lSY474NGaUfXgdKBjT+FNbr/nipSOBx1phByQKQyPHTnilC8c5+tO298U5aAIyueOfwoqY4+tFAXOMMYNRvF7VYUZ5pWUVz2PQ5rFQRkdqTaQas8fhRtB6UrFcxV5zUsbY708xc0eXilYLpliNs96kBzVaMYP0q2g3DtVozkrABUirj2pFHNSEg/WqRDFHfio5IxgGnBuTz+NOHI9KNxbFPlWPrV2CQFcelQSx8VGrbTSTsU1zI0wMjtTh0qCKQFRmpd3WtLmLQ8EZp6moN1PVzgetMTRPtDDJxVeaD0qymAOKU8jnGKZKdjHlhKmosFcVsSx5HSqcsWD6VDiaxncijk55/CpRhhUPlkdKchxSB+Qrrx2qJhVjrjFMZBTaBMiV2VutaNrcHpn8KoFec0RsVNJaBJJo6FJAwpGOe1ZsE/TJ6etXUfcK0TuYONh2PxpMc/4VIASacEyPpTJuNReRUuOMdh7UnIxjpQTQICKQDgml704jP1oAapxjpxUytyKjC9qcOODQA9jk0L6dKAcdfzpwAoAeowPel+vNCjipFXPIoAiI/xoYd81OQAOKjOF/H1oAhPFIeAORmnHHtR16c+1IdiJzk4qL8OKnZck560gj/lTFsRY/lTCORU5TI57U3y+fWgLkWOvrTeenNT7Mcd6YwoHcQe9OJAHHPem4x0HFNY44oELjPXHNNI4HpSbs5pc8cUDEHUfoKcoAAppPH8qcDQAHIyDUZOegp5IxzmkH3ulAIBxx3oPUYHNOFJ1Hy9aAEBwOaKb0PH60UBY5JDnpT89qgQ/TFTKQRXMeg0IVwaQcVMBmmsuSe1MExo4+tPABphXFCnHXpSHYeFwTUytjtVfeD0o+Ymi4WuWt4NMaT/IqMA5zSiMk5ouHKh6vmpQxH1piRH0qYRGmiHYaeRzVeRe9XFjOeaR48rxVWuSnYqxSEcVcjfcB3qk8WDUkLlep4FJOw5K+pex6UAn1pI3DA0jVoZFiNsipgePeqcb9BVlDTTIaJH5B6/nVaQZ96sjkcU2SPNMlOxTK5pjJUzrg59KAM9RUmlyDBFO256VKV7ilVRmiwXK7LimEYq2yioZFpWGmRq208CrtvJ05qiw/KljYq340J2G1dHQQkEVY2gVk2s+OprQWTPStEzllFpkhUCmbRTgwPXGKU0xDNvrTx1570HH40g5OKQEoXI6UpTI4pYwT9asKoxTAqFSB06UqkZ96syRj8TXofw70K1Sxa91G0824kJEMcg7euPSs6k1BXZtSpuq+VHFaJpc2qXKwwkKP4nYcLXY6f8AD8yMWubo+WOyrgmu+sdPhtyzJFGhY5KoMCr1zMtrABHGZJW4VRXDUxUntoj1KWBhFXlqzkYfAmmInzRM57lmNOt/B+mWU/mpZxS5GNkwLD8K7W2ZHiHmRgNjn5jStbrICRkDtg81lzz7m3LTWjivuOKfwzoE19HLcaeIAnUJ/q2+orRvvB2h3cGyOwhQE7t8YwfzrX1TULXRbIPOGZmO2ONeWkPoK55DresAM7GwhY58uM8kdgTQ6zXUl0IS2VkZOt+CvDsNhK3nmydPm3tJk8dsGvJPOgM7xQyiTBIHGMj1r1vxJ4Ts3tneecrP13sck146YxFqbYwcEjcK3oVpydmcmJoU4xui2ACcHFOKD60zPPTFPB9a7zzLDHUDNR7eOKlY84FJ1pgQMvr+NROvcirTgcf5xUTCkNMrlaAO1SFPakx60DIj1o6DpxTiB70h547GgY2lGTSE4OelKM0gHqf/ANVKPpTOh9KUH1zimKwjgZ5opG9qKQziVJFTxvVcduKenFcqZ6TRcUmlHX1qOFuwwcVKcdqszAoD1ppj5qQGpVxxRuMrrFz0qVIRwAOKnUe1aug6RJql4sS7liHLvjoP8aTtFXY4qU3yozLe1eeRY4Y2dyeFUZrobHwbqlwA3lxxg/3mr0rw54fihCRWVvub+8B/M11t7o8lhZGeV4sqM7F5z/8AXrmlXk9Yo7lhYR0qPU8YPgPUgMeZBu64yapXnhHVrZC5gWRR/cbNe32caXUYKBTkZzmnm05wU4pRrz3Llg6e2x85SRmNyrqVYdmGDSYB+te66x4ZstSiYTQLn+8ByPxrzLxF4PvNLzJAGuIfZfmFbwrp6M4auElDVanJvHkZqq8eCeOavEEEgjkU0ruWt3qct7FONipqcNuWmPEVamjikhvUmXA5qeNuPeq4I/GnIfeqTIaLyNxmn54xjPtVWNvTpU6MCKq5k0JIuagK4q0ck4qNl7UDTIcHml20u2lxQMTHAqF159amI5OOlIVoGmVStNIxVhxio+x71JSYsLEN+NaUEvFZdWYZMEDtTTsKSuaqsPWplGetUom981bjfA61aOeSJNtKFpAwIzmng+mKZI9BxxVhegzVZTnGDitPQ4IrrU7eG5fZC7fMfak3ZDUbux2Hw5gsStxdXlus0qHbGCM8+1ei2NuTmaUDzG/ujhR2ArM0XTbWFh9iiEcC8ICOT7/jXRonAFeZUnzyue9Qo+ygk9yMD5s+lNiQTXDuw4TgVZIxnFQWkZMkhLkDdWTV2dDlZFtApTgcDtTL25jtIPNcFsHCqvVj6VMq4wOlZbZvrwkjEUeVU+3c/j0/ClKVjJK+5SsLFry6+23/AM78hB2Qeg9vfvWlPIIlKxcnHGKklbYAqKPw4qtNhUbcSzE9MdqhaFPU4zxeGOnzyyn5hwoB45rxuHLXTHnHPWvY/F8b3Fk6E7WbIGP4U7mvIo4xHdTqOQDgGunC/FY5MbflHFM80DIHIqZVLMFRSzE4AAyT7V0umeB9Xv4fNZUt1PQSdcfSvQlOMd2eZClKp8KucpQM4xmup1HwRrFmjOIlnUc/uzz+Vc1LHJDIY5o3jfP3WGDRGcZbMJ0pw+JERWm7MnjqRUpx3pjHNWZDCnA6Ypjp7cVIeOpprHjNAEDRnPSkKcfSpC3UUBuaQyMpntg0jL36D0qUnqTxTSf/ANdAEeM9KMdMGnEnp7/nRnpQMaQAaKRv1ooA4he9L2GKQA+tPXNcp6g6L5c8AZ5OKspz2qFAOM1PF9KpEMeq1IgpR9KXtTEPjG5gO54r1HwxbRWdlGoIAxye7H2ry+NWzuVWODnIFeg+EtQhvY4wCxkThgexrkxMmrI9HARWr6npGl3s21EhURIOmOp+tdHCftKbZCSxGOa5TTtm3esgAHH41r292Yypzx9azi+5tON3oJeaTLpjNc6eWaPO54ic/iP8K0bG7jvYVfAyeuKntryOZSCQT71jSxHTr/MXFvKc7f7p9KdlHbYak5q0tzXeAZPFULi1WTIOK00l+UlunUU07d2cYJptEps8t8UeCI7lnnsgI5jzx91q80urSazuXguYykqHBBr6WuIQyk7RjpXE+MPDEOpQs4QJMPuyY6fWtKdVwdnsctfDqprHRni7IDULR4b6da0b61lsrp7e4XEiHB9/eq+3P1rtVnseW7xdmVduDnFKFzirIj/L0oMfGadhXIV4J96sRE9ahYEdKkiOMelCE9SygyOKcUyKSNs8VJwRxVGTIhGCTThCMZNKTg8dakjbP9aAbZCYPY00xc/yq4RgZoKjNOwuYzZYeMgc1VePAPFbLR5B7VWliFJouMzN2HpSqCOasbcNimyIB04qLGnMOSbA7U4XBxjPNViO1OVc/WhNhZF2O5561ZS46c1mbcGlBNO5PIma6zj8a7vwHowuWhvpjvHO1fT3rzOMSOwVc5JwMV734J08Wml2sOBuVefc1hiKjUbLqdeDoJz5n0Ou0+ELGOtXgPTrUEOAoxkVYVehriPSYoXHPc9aIYtpZiep4FNuGZYSVGTU0eSoPfHSgmTIbwttWKM4eQ4yP4R3P5UiqI49xGN3GB6dqlCiS4f1RQv502X5pMA8LWbEQlflycZ+tVbj7uDySKutknA6elVbnIXlSD6Uikcv4nC/ZZ8AgnAOa8alXF3OR0LetexeKW2WEjdFXj6mvKbK0a+vxCnLSyba3wr/AHl+yMcbG9JJdWdz8NPDqSL/AGndJlycQg9B716XbjZKFA5xnJ7VV0S0WzsYYIgFVFAAFXSNtyj9B0qZSc3zM2hTVKPIh2qLm35JyB2rz7XNFi1ayuFaP9/H80cg6g+h9q7nWpT5ZAyFAxWXbKI7GeR1HzjvRdqV0XGCcLSV7ngk0ckMskUq4dDtYVBnnmvSJfBja5fSXqXaQRSNjbtyeKzNb+H19Y27TWtxHchBkoFIYj2rvhWjJI8WrhZwk0locSSPxpjN+VDZDFTnI6+1BGRW1zmasRt1pOcY6U5h2oKmmIbkge9MYsT25qXYQPamshxQIi3EDrS7/TrSOpH+FRNketBViXPocUVWJweSTRSuOxy2MCnJSkcUKK5z0STbUsYwabGOlS4IHy4z70ySaNWkZVQFmY4AHU16R4G8K2U+2S7bzJSO4+Vfp71y3gK0S516PzRlYxux75r0Xw+W0y9mt342SHGR71z1ajTS6HdhaCkuZ79DqrvSrKyRUQhgVGCUAH0rA1XwxbyN9qs08m6XkMowG9jXX35jutILpguoBH50ip5luhI6DBrmnC7O+lJxR5/purLHM9ve/ubuP+DPX/61bcV6ZsYPyntmsrxhoi3NxHcj93OnAkB6CqGnyXdjOsd6u7HIZeQRWKk46M6XGMtVud3YsUxuOB1q9eypJHEuCWLcZ9q5y3u3mQFeTnG3vW3ptuwIeX5m6deBW3PpZHHONndmzb5CKpNTKpJ+bO2o4gFA7ip1JJz6VaZjcVozjmqV3GHGCOOlav8ADx1qtNEDn+VDRKZ5p448OpewmSPiZOVIH6V5TIjRSNHIpDqcEHsa+itQg3IwIyP5V5H470U205vIlwCcP/jW+HqWfKzlxdFSXOtzkt2B/OmvyaMce9Lj2ruPKInFInDc8VKUzTdvPTrQFyWOpweOetV14PoKkQ8+lMliuMCmo2CKc4yKhzg0Ai+hz05p2OOoqvC2cVPkEYpozasIMDimSjI7Zpx/XrSMMqaBoz5uDUWGNX3iDelItv68ipsaKRnrGc45qUIQOlaIgHcc04wego5Q9oZeD6YFKi/U1dkg56VHsxnilYpSuaXhu3WbV7ZXUsA27ivetDG2FQMV4p4JVW1lM9QK9r0xiqADtXDiH71j1sGv3d+5vwAkCrsY+XH86pWudqnnmrqnIrBG0iKWWNJY0dgNxwuT1NTjnGT9aq3Vus5QMdxVtw46VbUYz6UMl2I7YfLO/J3ScfQDioh8zMferNuMWreu41X5Ue1QwQxmIORVW4cbCM1YkwVJ7/SqFycL1x7mpKRzfjDDacYweW6Vx3w6tPP12SRulupyfc10njKV47cheT05rI+Ex8y71DpuZhnjtV03aMn8iqivKC+Z6tartXHJp0gz1p0A2rjFIxBB9qBN6lKWFGHOaxtfuTDp8wT7204+uK3XIwTXK+Ila4nt7ZScySAfhQ3ZGtPWSuaHhO3FppsKsSXI3Nn1NXb5xLnBwR0os4WgUA5YD86hljZ5s4+XrVXSVkKVnJs84+IXh+OA/brRNpIy6qOvvXA5B7//AF69y8WLG+mSBsbdpHNeDSHEjjsCRXZh5t3izy8dRSamupPxmgY29xUIfnvigyHGe9dVzznEkJphIqJmOeaaSfxouKxIxHANRPjtTSR70wNjr+lA0hHAzRQ2KKCjlwc0o6dKiDVKhz0rmuehYmj7c1YXpVdOKs2ZDXESnoWFDdgUbux2GgwDQ1sbyU4kuX2n/ZHUV3t7GLmdLqJgGdRuxXK+JrE3nh6GO3GZ4yGUCtDwdqLXdmqzDEyDa4PYiuKo7vU9eklFK3Q7PTmlZVQZC98nrXRw4aIDHSsKwkUADjmtq2dcACpTY5sztYgDwyAgdOciuIhuQl+1hcEg4yjmvRNQj8yFl9q8m8bh7K8trtB8yN+Y9KylFuVkb05pQbZ3GnwqpA4z610NrlAoJP5Vx/hy+W6gjkU5yOK6y3lIVRninCxjVvcv+ZjrU0c3y8AYrPZ+fmyBU8BywIPHpWlzO2hrI3ABocZHHWoYQO5OD1qwTx0q1qYtWZmXa5QgVx/im0S5sZEI5K9K7mZQQfauc1WAOknFG2xSs1Zng0yeXIyHqpxTBzV7X4jDq90hHRqoDvnmvSi7pM8KpHlk0SDHpQV9KE9zxTwPlqzITbx/SgL6dKfg/jTqYrkZHy1E4AxirJGaYyZBIBoBMgV8HpVqN8iqrrikVtpNFxtXLw9zTlFQxtn61OOAOaZDEAB4xSjikbGOlC/exQIWNQgwNx5zlmzUgOeMcimYbgjGKkXnrigAZc84qNovyqzigDmhgmaHhWIwXguiQFB2YzzmvYNFfzI0OTnvXj1vY3hsmvYY2+zwkEt2Neo+FLjzrWFyeGGRXnYjSZ7uCd6J29sPkWpx1zVa3J2irSr1rE1Zn3Ru0Kygxkq/3VBwVPY+9aqZwCarXUi26CSQYiU/McdPerKMrJuQggjII71IpO9htrzbuOoEjVGRnp+tS24wJwP7+fzqLHBzSYELHj5QD29BVO6A2gDrVqTIAwOneqlw3YkHH6VDKRw/jjJhGM9D0HIqr8GIN0V3cdmkK/lWl4vib7JNKuRhCCB16Vf+FOmNYeGLVpFIeUGQ596uD91rzKmveUuyO0IAqCYVO3tUErDHNUQijPwDgmsOEG510ccRLn8TW1dt8h+lUvDse+a5mPJZ8flUPobQdk2bCR4XmoZ0GCRxV1xxgVUlOAQaozTucR41lePT5VUFi/yge9cLb+A9VngEx8pd3OGPNeia6izXMMTY5cHJrooolSAA88VdKo4t2FXoqolc+edT0u60y4MN3GUbsccH6GqRHbr3r2Hxxpw1C0aONN0g5X1BryOVHikaOQbXU4IPau6lU5zycRQdJ+RCU96CuKeDTXz3HNbHKRMMDFR4xUxpp9+1AyPB74xRTuuO9FFwOOIwaenQYowOlOAxXKemTRjI6cVradpV3OouIY8xqc5qjp1rJdTiKPqeSfQV6lYxxWnh91GMiPHNROVtDWlT5tTR0OLNohkG5ivSst7U6Vr/AJijbBcDGP8AaroNEwYYwOigVL4psjLo5kRf3sLCQYHPv+lcrfMjvXussWczAjbyP5V0FmScH8K5TQZRJAjeoFdZY4+uKhIpvQvsgZMnn2rzf4jWRNjPIB935vyr0pCM4x1rE8UWK3VnKmMhlIqno010Ji73i+p5X4G1Uw3BtGY/NytesWT5ALcg14CVl0zV/LY4eKUDPtnrXuekBBEnJbPIJNOpG0rrqRRm5Q5ZbrQ2htK425FT2yt2GM0kQXAGfwFW4/wPvSsPm0LMKYAzycd6mweRTUP0Poak7f4Va0MWyF0681lX9uCGI6mtgjINVrhN340wTseD/EOwa21UT7cLIME9s1yi8Yr2nx9o5vtPkVEy6jcuByTXjJUq7K4IYHBBHSuyhK8bdjzcXC0ubuPWpBweePSmAHginjr710I4mBIz3x7Uo59qQ9OnNKCMUyR2eO5NHWkPtSAn0oAGUEcVC0QBJA5FWlGQB3pSnHvQCdionA/pVmN+npTTGO9KBzx2oBu5Ix/EUq4zmmU5fSmIlPUDFKvBFMzkg4pw570ybEwOaeuM1GO/enigDr/CF759ncaRKCY5VJTjgV0/giBorNY5OShK/ka4jwrqSabqayTAeWw2sfT3r0nw2Y5A8sXKO5IPtXn4mNpXPZwNS9Ox1lsMKPWricjiqUHQdce9W09jXOdLHShTGwfG3HOaSBQkKqo+UDgU5gCpDcg8Gq2nxPAsiNKzxhvk3dVHpnvSYdC3bgiSftnBqNx8zexp8Lf6QwP8S5/Ko7glW4HPpUvYXUgl4B4x9fWs+4Uspxj6ir52kY3ZI45qnNwD3PtUtlxMXUIftEYQ4KsdjD+ddPYwpbW0cUa4RFAA9BWKtvh1BOS0gP4VuK2BinHcqew+RgB061TlbnOeKmZ+Diqc0nUVTYoorXjYVuKPDygWoI7sTVe+lCwSMTwFNXtDj22EIPB25pbst6RNLjBzVK6B2nHFW5CQBtIHPOfSqlyf8iqZnE5a+iM+pW8f+1nNbjQyiPap496z41U6xH9DXQfw560o6Gk5bHL3ELpLvkOQK8k8cQLBr8zRgBXw344r27UVBVjjFeN+PkI1RTjtW1B2nY5sWuak2zllbrzxTs56DFQtxx1pN/HevQR4zRK350xsf/XpN2frTuD2pkjQdvNFB4PWii4HIdTUqdD6UwD6VPawtPPHGnVjiuRux6qV9EdN4Ss3aCaRFzLL8q/SuzvLGaLR3LnAGKn8LafHbwogH3VHatfxCgGizDqDgD65rmcua7O+MeRKI7w+AYhkcYromRZbdlbkFcGuf0EBIEDdxzXRpgodvIqY6FzOL0E+RJJA55jcoD7ZrrbSbC4B6dq5C8T7N4iuFxgOQ4rcspvmGGB/XNZN2Zqlc6qCQYB4+gp1wFkhIIqhauCuDx9K0fvJgZ6VadzKSszxv4haG283tuhLJ9/HcetdX4O1BbvSbaQEFioB+orZ1mzWUMrKNpByMcEVyXhqIabd3Wnj7gbzIs9lPb86TeiXYtR95yXU9FgfcoIIOKuxkFdvTPYVgW1wQVAOBWvBLkkgjNO5DjY1YXJIX0qfPGM9az45Sw4yD0q2HAXHftzmmjNxH7sMRTXHy09RlRnrQMEVSIZkahFvDk9Mc141470Y2l8LuBMQyDL8YwfWvdLiMEN71zPiHTUvLV0kQNuGORmrhJwd0Z1KaqR5WeFDoAD1pavazpz6ZeNC2dh5UnuKo9MetehGSaujxpxcXZimk+lKTk8U01RAvtTgcnnimZGakXB+lMQ9ck+1ScYx3pqgcUpP5UyRCO1LjrQp5/wpVAoAZj3p6c00jBpyHHAoAc2M05KZnnrzUie54oESAcU4Uwnpk1dsrC8uyBa2s0pPdUJH50m7bjSb2I4VMkkagZ3ECvZvDUIgtIlA4Arzyx8MahbXVvPfwGGMtwDya9Q0pAkKiuLETTaSPXwVNxg2+ptwn5fpU6ZPTpVeH7ox1qdfUfjXKdZOvORVZZniuhG6kxvyrj+E+hp4YioJ7iOErJIcIOpPQUAkWs4u4iD1BXFLdDBFRCWOUwyxyI8e/hlIIOeKnuyMZ96l7C6lKTGMY5zTEVd3anHG7r1/SoZpFhR5GYKFHJJ4FSUMgG+6UgcEsfy4FXnHHFRukcM1qIzndAGz65NPZ6aVht3GEfKeeap3C8nk1Zd+OnFZ1zOArc4FNlRTMnV5QVSLPMrqn5muptkEcSgdhiuOP+la9ZxjlUJkOOntXaKcLj2pR3ZVVWSQspBFZtxIOSe1WpHznPT2rJu5RzjFNsiKKlmN+tjPZSa6UgYrmdAzNqE0uPlQbQfeujkbC01sOotbGZqZ/dnFeU+Lbdrq8kVVyyDIr1DUZAEYdK4+0txcateFhlVAHTNODtJNBKKlTcWeTyxkMVIO4etQFMdq6rxbp62moMyD5XrnWWvThJSV0eFVg6cnFlUZBp6nmpNg70m2rMmxmaKcB74opiOQXrW14XUHU1JHOKxRnP1re8KnbqIPtXBU+Fns0PjR61oKjaCe/SrfiobNFk9dy/zqroR3ck4A71f8Q20lxpN2FkZwUykW0fKR3z1Oa547HfL4jN0eUkLwdvrXVWrZHtXn+gXpZU4AOOa7aynBVTnIqEypK6MfxpbtFLBfxjCr+7k+h6frUWlPu2nOBnpXQavbJfafNb9nXGfQ1xOg3Jhne2n+SaI7SD/OlNa3Kpv3T0CyHX6ZNakRO0DFYWn3SsqjjPtWvBIGGSVzTiRNCXseVP0rhNUX7NrNrKMAMTGT9eld4ZUeIldwwSpyMc1xHjBSIWZBloyHGfY0p7F0dXY3bbbtHFaUGdw64PoazNOkWWJCp4YZrYjHHSmlczbsXoTwOtXYwSwxjgdTVC1OCQOnvV6NjkEAcVVjNssL1G4mngDBx3qMHI5qdBgetUZsryr+NUblMqcitJjycdRVW4GQeB9aYI8+8XaGl/A3yjzF5U+leWzwPDK0Uo2svBFe+38Y2EDnPBrzTxrpGZBcQA7gOcDrW9Cpyuz2OXFUOdcy3OI789aaeuKViM8j/wCtTBya7TyrDlqVOOlMUDFPXrzimSyQHjjpRn8RTf5UAj14pkjl68d6eB7cUxfSpAMYoQCFevrSEkfSntgio2PJpiQoPNSqO2KiUGpM0hmjoccEurW0d0m+EtyvrXvGnSwG3jt4YEijCjGzjtXgmiH/AIm9r/vivdNNXES/SuTEbnpYNe6yzc6ZHfvCZJZFWM52jHJq4mnRx7BGzKo65Oc1NCMKKsLXKzt5mNjtkA+UkH1z0qxHaptG4kn1zikQ1OjetKwrsga1AP32K+lVbyydkxCc+qv3rTb2qMik0NSaMGCy/syzlyqorMGGDwD2rRnuYXkWLePNddyr61bkXdG49QRTLRQI4cAAbOalq2xTlfVmRdTpbRNJKdqL1OM4rJ1rTrrXbFYbdJFgZg7HO3cB25rrSMMcAAZp8I+cVPKNTtqjFuQyaikQDFYoEjXj2p8hdBlwVHuK3JhhjxULDdkEZHvVNCUzAnlwuQf1rHvZW+YYJB4rrnsrdgQ0S8+lc/qNgYbgqwYxH7revtUtM2hURQ8PWp8+a6dcE/Kp9hXQGTAx1qG3CxxBBxiorh9q/eAoWhTfO7sW4m2g/NzWBqt2sUTH+LsPepb652/Ln65rM0K3bVNXDtn7PAck9i3pSb7Fxgkrs6rQbIWunxhvvuNzfU1ZuXKr1qUsFXFZ17PhT1q9lYw1lK5k6nc/Kc1n+GYxJFdT93kIBqnr98sMErlhx0GetavhRDF4fgMgwzguc+5zSi9TWSsjkfH1uPLZu4rz4n1r0X4gSfuHHevOCfXpXbhX7rR5WYr30/IX6ikJppP0ppNdZ5lgIBPOfwNFITjtmigdjkhx9a2NBYxXsbn7pOKxjW0kbJo0c8Yy0b7q4Kr0se3QV5XPU9GmAQAGunhcMu1uh6ivMvD2oLc26hWALDBPpXeabKAiqp+UAAVzRZ3yjocrqlq2jayVyfs1xlo/Y9xXSaVeKwUA/jU/iTSl1bTHiJxIPnRh2auK0W/ltbl7a7BSeM4INKSsyoPmR6dDJu4IrivGVi9lerqduPkJ2y4/Q10Gl3qSAAk/jVvUoo7qwmhkwySLjiluiU+WRz2iakJApUnmuqs58jrljzXB2FlJY3ZjYttB4PrXY6fwFJ69AKlFysbgOVJJ6Viaxa+YDvAINb9uuV+bvVTVYyoVR0Jz71TWhlGdmZulwGKJE7KK3ol4HPOM1l2Sc5zx7VqxHAB7Ec4qloTLVkinBGQcVajYhR2qqdpOc8jr71KnysvpQK1zRTJGRz3NTx5I98cVVjYcVajJPI6VaMmNdefTNV5+AQKtsMHvVeZc55zQETOulyhwa5vVrcOjAgYrp7rGz0+nase8Xg9DkdaV7M1Sujx7xPp32K7DoP3b/oaxQMV6T4msxcW7q3XHpXnLoUdlYcrwa76FTmVjx8ZR9nK62Y5T6804deaiz3HFSKf5V0HCx3f3pRj6U0fpSg89eKBDgakHNR+/FOB5piHk8VGTzzTuMUwnB60AiZe/BpGHpSA4FIT6mgESWtwbO4S44bYwYLXpln8Q7WytN9/pt1C62hu9m5csAcADPr1FeXkMwwi7myCFxnNF1o11rMtsbeC+8qGLyW+0IQQQGc4/2fSuPEvVWPVwKTi7nvdx4206z1HQLCWG4M2sorxFcYiDHA38/wAvSprrxvplquv+ZDcltFljiuFUDLlzgFOeRz3rw7UL25vpLTUUsbiSDTILOH7SqnbBg5Ib3JJFafieOSefVdesZGey1LVPsc4HQLhHQ/mD+VcfMzv9mj2JfG+k+Trb7bgf2QiPcDaMsHxjbzzjODXS6bdx31hbXkIYRXEayoG64YZGa+evE1tdQQ+I9VtSxt5L5tOuV6jbhWU/mK938LDb4Y0cD/nzi/8AQRTTInFJXRtg5WmYyKRWwKyda0qW/aN7W+ms5E/ijAOfYg02Qkm9TXHWm2w2oBjpuH61kW2n6lAVA1aWWMcHzYlJ/OrxjvljAieJm/iLqRn8qQ2l3JevWnxnDj2rIlk1uEkiytJxnjZIVOPxpkeq36SAXGjXS57xsGFSPl7G7I+9mPTBIqP6Vh654kh0iKKae1uXSbn5Iydh9G9K1LC5+12sc3lmPcM7TTvcXK0rlimSIsiFXAIPY0/tSd6YjA8xcsB0BI5qjeyDrmtDVYBBMHTpKTkehrIuVL54/H1qGdMNdTA1a4Zsww/NIx2qB711mhWMenWCRr9/qx9T3qhptgkcwmcfMOlaxkC5IqUrO5pOV1yofcSAKelYOoXGwOT0qzdzHBwa5TxDqKQQOSfm6AUNhGFjHnjfWdbjs48mNW3SHsBXdOVtoVjAwEGAKzvBGl/Y9PN3Mp864+ds9s1o6koKMc9OlNKyCTvK3Y838eXe+QRjqa4xhjr0rb8UvnVZF7KKxm6ZzXoYaNoX7njY+fNVt2Iz60lKRj1pDxXScA368UUhPNFAHKtyPSur8OqtzpzQuODwa5UHNdH4Pf8AfSRk9ecVwVVpc9vDP3rDNO36Rqr28p+QnKH+lek6Pdh4xluDXN+I9F+32iSRZ8+Plcd6zvDWpsGNvcDbMnBBrleh6CZ63aSCROK5zxloxuIhe2aAXMXLYH319Km0y+LYJYYHFbwdZIwepxnFPdWF8LucT4e1HcUz97vntXVRz7h16Vy2paeLXVHngXajnOPQ1r2MpIA7ipQ5WeqL88SyEH+IHrVq0OxgCORVYyfd/XFWIZAWwcCkLobtrNwD/DUN7N5vI5x2qjFcZ+UZ4ODTpJCSABz6CqvoTbUsaaRuwentWseBgfpWZaAKc84NaClcZJPoaEJ7j22jA6fXtUkbbh6VBktySMipYziPkdfSmBejyxI6Y9auRYKDBHWqMRUdd2PrVuMKOfm+hHNUjKRKegPB9zVWeQ4wOvtU7YC85FQSA4xnr3piiUZFyvNZl2Cuc5rWkIBxu56ZrNveGxk9O3aoZvFnL6v12nv6V5rrcYiv328K3avTNY4Rm9B0rzfXyGuwc8mt8NL37HJjoXp37GaTgUoOKQHjjrSn616J4YpbGe9ORvwqEt/nNPjOSD1pisWsdelHTtTVbApS2femQOyM803v70d//r0oHPpQAo46YpOR16UKAg4GBRnrzQNE9izrdwmHmXcNufWvZdHvdSjgCm1eQBSoLE5J6g5/SvGLKQRXcMjNhVYEk9q9r0HVrKaCMx3ULDblvn+6B3NcmI3R6WD+Fm5BqNxFBbpcWZluJcFxGMIOTyeO3H505bhbnT7+T7OsSRBcR+UGO/GScEYJ5Aqe2vI/s5l3Zj37AVOQecA1dmnWKGSVmGIwf4vTt9a5WdhnW0puZktn02A2lwqPP5ir97BJyAME/d/M1uoqxoqRqFVRhVAwAPTFQxSeZCj9Nyg4J6Z5wfzqVeAAetITJAaXmmA8UZxQIkHFO8wLtDHBPA96YKeFVmVj1AIB+tAiN5lXAYgO3RRzVVrhSEYuE3ELgckH0NTvERIm04Reo9eKhNsokRyzkpjr3xn/ABoKRLT046Dj2poPrT1oAXtSEU8DFJj8qBHOazHONQEjnMDKFT0U9xiqoXOSegrR1+8QTR2ajMjDzGOfujt+dUR9z5utQzeD0ET5Tnp7VFcyYB5FOkbrn8KyryTAPQ9qk1iUtTvxErEniuX0W1fxFrm+TJtYGy2ejH0pfEklxcZgskJd+BXceFNLTStIhi2/PtBY+pqUrvyN7qEb9TXG2OMRqNoUYArB1iYKj47VsTuATXHeJ7oLHKewHSqbMoRPNdZl83U7hs98VnMT7Gkln824lbrk0Zz3r1KStFI+frvmqNiZBzSMST60dD60hP51oYDWGe9FIaKAOWFafh2bydTQnjPFZn0p8TmOZHBxg1xzV42PWpS5ZJns2mkSRgH0rnvGGgtCw1HT1w4PzqO4q74bvhJAmeuB3rrIlSVNrgFGHeuVWejPSfu6nCeHdUE6DLEOOCK7GxvMZUnG7ua4zxFpB0TVEurcEW87bSMcKa1LO5ZlVx26GptbRjvfY3L9DL8xxgdqjtUKEc8e9Rxz+ZDjPFSRkBwPypMEXQQcjnPvUqnGcHn+dV1fBxkZxUqjnOSB/KkMspLlsA896mU7nxz9KpvhQM4+tXLXcxD4oA0oDjAPUdxV9QBg54IzVOAbiR6c5q/Fjr1HpVohsUAfN/M1NEAce1Q8MygfSrUXEYPShEsmRcKD1q0hIJ281XQA9SGHTJqZmC5GeenFWjJslDYU4696ruwOc/pQ7NjABx2quzNtJxn60DSIZ8N1Gay7w8k8k4q7KzAY/kaz5wdxOaho1joc7rEh8tgRz/KvN9dfN4MHPFeha04wxHHrXmmsPu1A47cfStMP8aMMa/3TIVP4U/A7jrUSn3qQEfQV6h4DGNx9Kch5GKRv88UidaALQPHXNKKYvSnqc80yB+Pm/CkBzntR25NM+tAD89h+NIDzmjqPSm/oKBokh5lUHpuGa9b8P6VZpbokc2yabEi5AJ49j1FeQRj5l7EmvWtItL3+zo1tJlEu0fvW5Ix2GfXPtXJiHselgtmdha2Ri0kWcMwDqd6yMnG7dnkDHGahXQpXlkmea2kkfcrK8bGM5537d33x2PpVS2i1hERxckuBkxnbtJ546dPu/rV61m1bbI8oChCOHUc9Nx4PQc4rlZ26os2GifZ7hXmmMyrIX+YtlzkkEjOOM4/AVv8AbrVDS55rmximuY1ikkG7YDkAdufpz+NXloJfmKX2rk1zuqeN9B0q8+y3975c3oVNdLtyCBWRrfhPR9cKtqVossqghZOhAPXkUO/QI8v2ihF4+8MvgDU4h7ngVqW3inRJuItRgbIBwGFcvc/CTw5OSf8ASY8/3WHH6Vlr8HdLh1BVg1C6W3dGkZdo3ZBHAPvk1N5I0tSfVnft4i0dnKf2jbbhwRvGc+lSpqVlKP3d1C30cV5/efB3R+Ps1/exswzubDc/pVBvhAmf3XiG6Qdv3Xf1+9SvIOSn3PUVuoWbas0ZPoGFWI5Bn1rymL4U38QZ7fxPcGVRlBsIHHr81d7osdza2UUN5Ms0yKAXVdoNNN9RSjH7Lub24UjsPxqqHJ9qcH96ozsY/imFF+y3gIWZXEZ/2lPaqRcFQQah8Ts41+z81iYHiPlr23A8/jSDHsBWb3N4LRCSuGPXms+eMvknkZqxNz0OKjXlhnOBUmq8inb2Cfag5A3dq6NZB5IBOCBis+MBSDxT2lwjZ/OqE9SK5nwGA/GvOfHeorBaSAHDHgV2Go3WxGYkDNeP+PLxp7gjPAoirtDm+WLMa2kLDk8mrynIx19axbKXoO1asb5UV6cHoeBVWpL3prH3pM803P61oYDsj0zRSCigDlh0zTJGHTPNPqvKa5ZHqR3Ow8H6j8ojJ5U16bYXgdUbI49K8J0W7Nveg5IDccV6fo94fKXnr71xtWZ6UJXib3jSVLnSRECCSc1z2klhbgEEEDABq7fyi5jIJ/8A11Vt1Ma8HntSbuCVtC5buVYAnj1FaUTdDx6ZrHifLgnj2rRhO1FGeagsvo4JGefpU6N8/Hfn6Vng7ZATnHX61aRiQCDgnigZcUqxAP45rRtHDEbR7VlovC5zgcVqWRzjPPpTFY1kTDDjANXkH4j0qlGcnjJFWtx6Yx9KpEMkXaPfNPU9VAxiov4hkf8A16evzEAimIuQYAyBz71MX7LjFVA2FwP/ANVEecEnr65qkZtXLDPge/rVWeTApZHwp5zVaV+zADPOKTZUYkTvlGqhdNhSfbirLvxz0qheHI9sVJZzGvyARtnrivM7p991K3XmvQPEsoSIkntXnIbfI7HjJrfDL37nJj3amkSing4HSmL2p/f+VegjxRe3vQp+lBpgOD0piLKkCpFOKhjPSpc0yWL68fSm9D16UpPHWmA9f1oAlzlRjmoyc9xTlPGKQj1pAgQ4kTP94V7Z4eI+xRHr8o6V4XPJsIOenNdX4U+IcVpNJBrX7uAY8qRBnb7GuXEX0PRwTSume127D1q7CwPpivLdN+Kmgzao9q7TQwdFuXX5GP8AMVtn4j+GoryO3+3+YzsFMiIdi+5NcfMluehyN7HoKNn61Oh4rKhvYGhWZZ4TEwyHDjBHsavwSrJGHRgynoynIp3IaLqNxUymqqN9amQ8UyCY1BIf9KiHco4/lUueOelQTHF3a+h3j9KT2BD5+Y4z7VWZu1WJCDbJ9Kps2D3zUspFyyP74BThipAJ6A4rndC/thmuzrQgID/uXiQpkZ7itu1cLcRn3pq3sE88sILLMkhj2OuDwM5+lA1oNBxSk+uKcy+lQXEqQRSTSsqRRqXdj0UDuadwOU17U7W/1qPT4WDzWR3ykfwkj7tSgjHPOK4bwdaXRvbzU55CftkrOCx5IJ4rsidgBzx3NRdvU6XFR0Q7+VJtG3ng+tIzqM0K3c80guS5AXNU7mcheanLcE9qzrtvkbk49KY0c/rt3hXHbFeVeK5Btd2PzMeK9D1yQncgySfavM/GSGMDeeSeBVQIq7GTYv0rat3ygFc9ZHpW7bHgdvWvQpbHkV1qXB29KQ9elOXkAnp6Ujjj9RWxyCBvWimjPrxRSA5Zmx0qvMc5qRziq8hNckmerBEauVkUg9DXeeHrwvAozyBXnzHmum8OTEIMZzXPI66bsd2kpdQOlSoAH9qzrWQuAQeAPSp4LpZYt8Tb19RUGxciYGU88+tX0bOOeRz7VlQnDBj1q7C/zhT0qbFGkvzAMe46VPHw4A6DvVSJ84zx3xUwk2ngDr3pDRrQBTznJJ6Vo2xOeBgVk2YLFMHjHNbluoUAZPHSmhvQ0bcEKG6e3pVrJC5/Oq6MoB5+v1p/zZJ9ePaqM9yTnHAx70+NyTx19abuAAbPanxkFdxOcimhEwPABFP3ggkiq5kxnPWnbwwGTxTJsSNyRiqlyQuSTnBqSSQEHBIUd6ouSwJ9aTZUUIX4P06VQun+XGOlWJSFHPQVm3soAOaSKscX4xn2xyHPGK4GF66fx7dhLfA6scc1x9rLkAE9q6sNpdnm453sjTRqkz71WViVBpwPU5rtueW0WOM9eKaevHWmBuBShsmgRMhIqYHPWoEbPWpRTJYrEYpqjJ5pW/ShBgcj8aAHn1zQ3A/rR0xnrQx684oEZt6SFIBrnrxuTXQ3mCK5y9+8frXPVO/DjdNBlvFi/v8AFeq+HvCto1mDcEl2HTHSvIbaYwXUco/hYGvefDN0lxaQtjqAQa4pJXPVpydrIfZ+A7HKtJLKUJ4XPFbOneH7zRJ/P8PahLb7uHif5o3+oNakEmECq351pW7YUKefep5V2NOeXVlYJ4mvxun1dLLb0W2hHP1Jq7H4h13TcQ3mljU1HAuLY7Gb/eU8D8KuxN8nHFTQ4ILHt1FFl0Iv3SKA8WawZN7eHZVtwfmHm/Pj2XvWhJ4o0yZrd45JFkjYs8UkZV1GPSpY8AEHk9qy9Wgje6sSyqcy4JA59aTvbcVot7WLdt4ptZ5Ggkt7qCJGI+0SJhCc1Zn1WwjiMpvYNnr5gqrp8CLLcR7flDdO3rUE2k2pufMFtFv6k4qNR8sLmtpuoWl9h7S4ilAPIVskfhWhdfZE1ISSeWt3s4LHB298Vyr6NbSzq4Vo5BxviYqfzFR6jpBuJreGWed7fLb90hLNwMAHqBVJslxjfc3NZ1uw023d5p42lx8kCMGkkPYBeteX6vp/iPxJcLJq159nsmYMLSI/Kq+h9fxrt7TQ9Ps38yC3UTH+Nvmb8zU0sQAI29OlDV9yoNQ+ExYIfJgEajAUAfUCm+YScfp6Vbmjxyp4FUSSr5HTHeky0TJncM9u1O8wAEjrVeOTLHPFG8gH0pXCxMHPJPQ9qzr5+GH61YZyV4rKvpNqkmmMxNSIDc+teW+OZvMv1XPArv8AWLwIGZjwK8r1ydrrUHcg7c8ZrWCMarGWQ6VuWvTk1j2a1sW+ABXdTR5VZ6l9OlDcnimKflpd/HFbHINbrzge1FBbmigDkGzVeTpVph1qtLXHI9WLKjda2vDkhDOpzisV+taOgvtumU9xWDOmJ31k5CDnmrSlFztwAOw6VlWcoxgmrUbEqecGs2dCLyynIAPTmr0LkkgdOmcVkBj5i5rSsycZyKQy/wCcYgONxY4AFaNsnI3HgHnNULdv3ig8nrxWjE3A9fepLRrW23qBmtW0xkE8+9ZNscbQTyR0Fa9uMRhmIGPSmgaL0Ay+cnHp61OgxngY9DVeI/PweKnAxy3H1qkQxykbcdacrAJyehqNWHOTTV4Qkc4pisPlbLY5FBJI5P41G2Co44PSoZZwv3sbqVykuxPLIFXHUelQPIPL54Pt2qB3ZyWyRUEhJAGevpSK5SSRjg1jahINrZ6Vp8AkbsEVgazKFVgD0FMhnl3xEu2NzDHk9zWBYycip/HM4l1dQOirWbYt8wrppaHn4lXbOlgORwKm296qWjcDPSruRiu1Hly3G7aAvNPXninFcD3pkCx54qUVGpxjNKW+lMQ8n86UMPWoN1LkjFAWJweaa7cdabyD3pjmgSRSu2ODXPXp5IrdumOOnSufvT8xrnqndhyix5r1/wCHl75mk24J5Ubf1rx09a734c3YEckBPKtkD61xyPTp7ntNs3yrk/jWvZOCmM8iudsZSYFBXitSyc4z0NQbWN+OTB+8PpVpHH596yonHTqTVtZD2pXDlNFGwM9cdTVLU+JrMntMP5VPE5YAHiq2uN5dmJmO0ROrn8DQ9hW1LlvJtvZ+MhsdPpU8nMnHU1SeRhKs1t5bmZVK8+/etiEAfeILnrRGLZlKSiRQWzHDSHFSS2oeQOWwR7VYBx+NNZq0UUjFzbZUa2IGNwz9Kgls2YcOAT7VdZjng01jng9fSnyoOZmRLpsgHLqQDzxVebRQAXadFU+gzW+W49aquqDlOPUUuRFKpIwTpkflF2mKx54YjANNW0tpEwZ+ey55Na98POgC7GeNsg47H+lcFfXQ+2xkx9V8otnIyOR+NNRQ+eXc6RrSJAR196qzWNvIh3AHHqKxhdSQsTFIw9s8VIdRkD7nAbI5xxVqK7EtyfUddaTaTBonhjGf9mvPvH3h+1trFpIIkDZ6gc16GNREuS5wcYrkPHLu2nyCCF5CRjCjJrWNrGE7nldoAMDvWnCMjJqlbxOjbZEKt3BGCK0Y8ADitYHJVepIOnNDUueKQ960MBhooYZ54FFMZypxgioJKeDmmPzXIz0loVZBUunv5d0h96bIKjQ7XU+9YSR0RZ2lnIck549K0IpCRgcHFYljITEvpWjbPg+tZM6Is0EfrzWjbSY+nWsmNsitGzG7FI0Rt2Rwc5+Zu1akBBGTyx71k2oACnPNa8AwAdvOOtSUaVowySenpWtbkui5xxx9KxLX15z3962rRgvUUIbL4dgvAGBUodnAXqPU1WLgAEfNnpT1cso5AHFWTYl3AZ55+lMefChUHyg96ZtywPPPBzR5eFIJ47GgEkRS3D4IBJ9BUMeWJ3DgfrTmb5zjj+lBJ2DkH8Kk02QrMNhA+97UxiBEGwQaYCSSTwOpps7buB2GcUyGVp5iGOeD7VzOuSlInJzzW5O3EgPc964vxTc7beRmPTP0polnlevTmfVpmzwDgUWB5qjK3mTOx5LMTV2xHzV0U9zz6uqOisun4VoDpWbZthRWgjZ7V3RPLnuOjyDnNTEjFR4AIpc/h3pmYu70pjNzxTWb05o47Gi4WHD3qQcfWmLUh68GgTEzgcVG545p5/nTXBPNAIzrs8GsC96muhulyCawb5OSawqo7aDMsnmuh8E3Bh1XaDjeOPwrnX4NXdHnNvqVvIOzAVxs9GJ9C6TPvtVYHtWvZyYwAe/euV8OzF4QRz6Cuhjb7rD24qDoOgjb5Rg81eg6c4rHtZA67ieavwMT1PFJldDRRuDj8KNST7RYyxgA7lzUEBJO0ntViM8MPbiluJ6HK6NroGpW+m+Zv2ghQRgoB6nvXb6dIZGJJ4xXNa7ptukJvoYVF1F84ZRyR3/TNbmgzLNbo4x8wB4q6aaVmzKuouzijaHNNZsUA4zTHPH0rQ5hjH0600Hr6jvUchIPFOBHQ/mKAFZjjjoOaqTNknnFWHPfoB2qnLkk5NMBl46m2iXIH7xeoPP0xXnmsbo3JfKsLjdkgA89sdq9DdwIwewYdQTXBeI0KW9z824o4YKccDPX2pLcroVZXyR9Ka7DIznNVvM3H3xUkp+UfzFakkyvz6n1qwh34BAIx3FVIx0OatQ8/wCNAmzznxhAI/EM2BgFVIAHtWURt5rpfH6ousIw3bmQZ9MVzfUZrohsefV+JiZ7c4pQ3cU1h15/Cm5wTVmRJnI9KKaDRQBygUg80uzIFA4Oakx3rnPQuVJI6qyDaa0ZBkVRnHNZTRtTZuaXJ+5HNakT+nccVg6Q37vHNbUDZHOfasJHVHY0oSCowDWpaHHtiseAktx0rVtgd6k9uMVmzaJu2Yxgg8ZrUh5Q9BzjrWTatjaO4NaNuTtwxPPTFI1SNi2GRnFaVtlEHQBecGsq0Y9OOmavIx6ZJzjpTRLXQ0UYgcgY7f41PHw/znhR0qohJzzwDVhXJ6jrxVEsm35GTnmmkk7QxIANNB+Xnt0PpQH28kkn+tAiBh3x0Pao2Owcn6ZpxZg7AioZmyMYxnmpLYgkJbB4FQzHMmMkDHUdaeDheByapXEmJQTnpxTI3ZVv5Dk88mvOPG9yVs5MnBxiu6vpjtJHU8CvL/Hs/wAqRj/9dNETdkcYnWtOyXpWbF1rXsFrpprU4Kr0Ne0HAq/HVKA4Aq2p4rsR5styVm5FMJ9KRm9abk/5NNsmw/dSrk/WmIOualQDOeaBCg08HOaQHP1oAHfk0xCj+VJwO9KWAyByajPGQetAFe5Oc1iXY61sXJ+U+lY111P5VlM6aRlTL8xqNDtYEdQc1NN1NQGuSSPRiz23wfcCWwt3JyGQZI9a6qJzGOvNef8AgGbdpVuCcHBH5Gu5RhgDJJB9axOtao3LRwQMdz6VpWbg+2D+VY1k2BjrWlb5UcZznNSy7aGknD5GQaliJCdQGHFVEkyueSQanjfC88e1AuhPNiRGjPRhjmqfgyQrFJbPkNC7Jjvx0rMiu3ub1nmvHiiRymxB1PvVnw6/l+J7mItjzoxKB0yQcH+lVF6mc17jO27VHJ0yOlPxz7VFIeOTWpxkLkCmI3JAxTZH5PUVHv2jpwe9MZK5GOB06VUlY5OSKfJMNuAD0qq8gI7/AFxTAWba1rNuwEwSc9q4jxW277QgkbBj3dMIxGOBn+vSu3hZSjK/A/pXnviUvcG4B8wnDBFbgIPXHpU21KWxm2TFmXOOg7VblOSDj25rMtm8uVeeCAPrV7JOccD2rUksRt6HHpxVuI4HYVSjwD/hUytg4zzQJnLeP1zeW0mOq45rlewwa7Dxuu61t37hsVxrcjNdENjgqr3mKTyajIB6dKTdzzSkjBzVGQoz6ZopM4ooA5omlXPtTTyeOlOXpXOd4jciqk44q4/t0qrNUyLgTaUcB627fp14rB004L81u2fI59O1c0tzshsaNqc9OK17JhuGO1Y1vwQP0rYs8bh0x796zkdEDZt2UlT3J6VqxMCwGR+VYsHGD17VqwOd6gLwMc1Nzaxs2ZG0k9OKvQ7S27kED171nwtk4XvzV+PgjkkmqRLLCsAvy9/yqZZQYtpwAeKgUbVG4Db2FQli0uMHk560yLXLqyZk+U5AHfvUu75Sc8+wqpGegOAcVMrBRjOewPtQNjGOQWJ5zyOwqBpdwK8dODT5jxtXI47VWYnOQMfSgGEhKx9enPNUpH2kbuvSrFw/bOf5VRuG+XjuehoIKGpygbuhOMDivJvGzlriMHuSa9O1Ns7jjnpmvKvGLA6ggHQKf51UdzKexiwj5q2bJelZVsMmtqzGMZrrpo8+szRiGAOKnX6VArcYxUitzXSjhZOOetNIB6d6QE8UBh+FMkcOAMUof0o7DtTcYPHWgQ/fTw/pUWMgdeaUDvmgLEuc9uKaTxSD60uaBFW4XOfesy4hJzxW26Z+tRNBnqBUuNzWE7HKzxEE8VVYYNdLdWoOeKxbuHaTXPOFjupVLnafDqfNq0ecFHyK9LQ5iAAz3FeQeAZSl7KgPBxxXrlpzExHpxXKzvg9DWs+cknp6VrW75QGsOzYgEdMcE1sWPIxnrUGpdjGTkY56k1YZdqls/LioEIAB79OlOkf9y/OeDmhC3OPlspZJLxH3ALJvBHXnofpV3RNVMmqwPLBGt1axlVk/ve+PWtbTbyWCFiEBmAIDYycelcrd3P2a8aQxtvJycjBFKTSXMgjfWEjqL7WdTkRk81g5B+6MAVyl54g1OJpA1xKBGuSSeprWh8R2jxxxfvI3GfnIBzXN3KtqGoxR4I81xwf7oPNZzqN7FQpq9rFD/hJvEUgzBcTEHphaf8A8JV4pUDDy+hJQGvR1s4UiAjiUD2WormCJQcKq49BxV6rqHuP7J59J4q8UquIZCTjJLRD+VV5PGfilABKRuxyPKGD7133koBhVXkZ6VVuIkIOUXOMZxTu+4OMP5Tzx/Hniu2JbMGe+6AVXn+IV1MGjvbKGcH7zjKE12d5axOdrRqQQRyOtc1f6BZkZ8sKfampPuS4R7FCy8WWslwWmD26njGM/wAq6Sz1zTbhMR3UHPUZ2k1y/wDY1mikFAfrWNqekwRxs9ucOP4a1jUkYSpx6HqcM8ci7kdWHbaRg09WwAQevavAzeXMEreTcSx4P8LkVpWHiDVYyAt/OR6M2a1UrmDVkeneMz/xLosn+P0rjOtK2r3l9brHdS+YoOeaQEY68V0w21PPqtOWhGRg0hyPpUrY/OmHODVmREW5opr+36UVJRz2eMGnhjjioc804E4FYXO2xMe+KrSjNSgnmmSjik9hx0YlhwXrctCNue2KxLLgvWzZnAzkVzS3O2nsacPLKtbNmCMelYtqSWBGa27Urx8vasmdMTVgOQAP4a0rTBlBJ+X1rLgJOAa0YmDYAOB/OpRqmbMODwvQCrUeF3EZ+tZ1tIe+cD9at7sqV6A8iqEy+0vy98jkVDFgS8dRnNMLZNKi/Ljoc9aZK0LaMDz7YpTIQeeMiq6/KpU/XPtTmbLDJz6DNAC7mJLH1/OopOw9ualdsqMHknmqzn5jzk4PHtQSQ3bDJFU5sgrnrn0qxISWCkDPrVWU988rTE9DH1h1jVh3NeT+KGL6gpP93+tem62+7JU8Y2ivMvEw/wCJio9Fqo7mFTYq2S5NbdoBWRZr04rZthx/Su6mtDzKzLIpw6imAj05p4HvWxzDuDnj86AeevNIaAeOKBEoNOjbPWos5OKeueD3pk2J2X0phXB4xQHp+9T6UxDD3yKcDSOO9NPB4pASZ49aQfSmg+5o3d+lAENwBg1i36ZzW5Kc5JrKvV61nNXRvRdmJ4RYx6s3Gflr2KwbcgIPVRXjnho7dZA9VNet6PIPs6Z5I7V589z2KWqNy2wGAPOa1LZ8Ec96yIsgqccH1rRt/mXJOPpUM6UavmKEYHp/Opo23YzyOgrORyU54J9R0q1Ax4HIxxSQmrIq30TwkvFwOxHOKzJLqZuJGjdR/ero8KT8w+Umq0thZ3DEvCmfYUnG+w4yS3RjXbxeQJEjgD9AcDNN8P6ZJ9ra+ueT0WtWPTLRHysKk9ge1WiwwAuAo7dKShZ3ZXNpaIshYAdAeenpWbPK3zbjxnOKtSy7o+eOelUJhub73I70MIody3O7tmq13ja2O1ODkqCMqPeobgEoSOtCE9zPuBhAVrKuOVAY7j64xWjcOoLcAEVnXDAE4xj3pkswrolZGz07YrM1JtlgWOOcmr2o/LM3WsbxFL5enAAg8fnVxMJ7HDStulc+pNTW77SKrE5JpyHmtU7GEldHTWMwK1fU9O/0rC05+BWwhyBXZB3R51WNmS5oGaZn0pSewqzIGHNFNO7t1oouBzIpy4/Cmr1pfSuY7yQYpsmMGheKRzxTBCW3DNWvan5Rgc1j2/8ArDWvb9Ae9c09ztp7GzaD5TjvWnagkg+lZ1oOAK07UdM96xZ0xNOEcDAPHP1q9E3cA4PY1Qt+h9q0oeOAO1BdzQgG04AGTjJq0rcBs4+tVIeBxUqkncD0p2FcupncCQRSq5UkkHB/lVVpmEbcDjipbZmEaAsW4ySe9AF0sMjOeePSkLAEnGM89McVE3ITPOaUnLYNMkeXwNvJ9gagOVLd88mpGAwT7VDnkfTNAFWcEnpVK4fZExz061PdysJ1Tsykn9KoXTHy+tAmzG1M5PzcH71edeJBnUAR0xXf37FsknnpXCeJAPt8Q/2f61cNznq7Fe0HHA5rXt+nvWZaDCitGL1rugjy6urLKgEcHml9cVGGOaeDkVoYBk84/nSjNNB708dKAFHPNSA8VGOn0pxOKZI/qKaCQfpSA5FGPmA9qAJd+aM5/KolJxTx0oFYGOD1pm4k4pSx/Sl7imNCYyOao3g4PFaHqKp3ag5qZbFwepT0MbdZjI969X0JgbVQ/qa8n0/5dVTFepaTwQB0yBXn1dz2MPrE6KJsEAn8MVo2rlTz0rH3FFyvUEVdjlYFD69axZ1pGxGFLHnjP61Io2k89efxqrC5K54zmpwx8wDjFCEy6g+XLkHJ/KnSIoU4OMmqnmN5YpgY5PPUZpiSZa2jqTz04qMsGJHIPfiqcsr7SM9DUcc8gwd2Tg9aVyrOxJdHg85x2qtnPDjDL0qWRzg9M5FVn5i3HqRSaLQ18EkKRgdjVOaU4xzirLAEA+2az5WJjkBxx0qUIo3L45GMnms6STdyTxnHpU90xJyT0qi/AX3NMGtDO1VjvDY/SuX8UyYs1HTjGK6TVidh9q5LxYcQRAelaxOWZzBNKppp605Bk1ojFmrpx/KtqI/KOeKxbAYUVswKCK66exwVtybPfjNJnnrSbQepNOCjHetDAQk570UYoouB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If you have a bunion, wearing a night splint might help straighten your big toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jill Ferrari, PhD, BSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1537=[""].join("\n");
var outline_f1_32_1537=null;
var title_f1_32_1538="Leukoedema";
var content_f1_32_1538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Leukoedema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White-gray edematous plaques are present on the buccal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1538=[""].join("\n");
var outline_f1_32_1538=null;
var title_f1_32_1539="ECG Managed ventricular pacing";
var content_f1_32_1539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing managed ventricular pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Managed ventricular pacing: a normal response for the algorithm when intrinsic ventricular conduction does not occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1539=[""].join("\n");
var outline_f1_32_1539=null;
var title_f1_32_1540="Arteries of the neck";
var content_f1_32_1540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Arteries of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vertebral arteries arise from the subclavian arteries. They angle backwards to the transverse processes of C6 and run superiorly through the transverse foramina of C6-C1 to the inferior surface of the skull. The vertebral arteries join together at the base of the brain to form the basilar artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1540=[""].join("\n");
var outline_f1_32_1540=null;
var title_f1_32_1541="Guanfacine: Patient drug information";
var content_f1_32_1541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guanfacine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=see_link\">",
"     see \"Guanfacine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     see \"Guanfacine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intuniv&reg;;",
"     </li>",
"     <li>",
"      Tenex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guanfacine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with high-fat meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11750 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1541=[""].join("\n");
var outline_f1_32_1541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030677\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030676\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030681\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030682\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030684\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030679\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030680\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030685\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030686\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/17/32023?source=related_link\">",
"      Guanfacine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=related_link\">",
"      Guanfacine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_32_1542="Metolazone: Drug information";
var content_f1_32_1542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metolazone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/46/5861?source=see_link\">",
"    see \"Metolazone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/50/30501?source=see_link\">",
"    see \"Metolazone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zaroxolyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zaroxolyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide-Related",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Oral: Initial: 2.5-10 mg once daily; may increase as necessary to 20 mg once daily (ACC/AHA 2009 Heart Failure Guidelines);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing frequency may be adjusted based on patient-specific diuretic needs (eg, administration every other day or weekly) (Lindenfeld, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-5 mg/dose every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 2.5 mg/day or every other day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F195713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not dialyzable (0% to 5%) via hemo- or peritoneal dialysis; supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaroxolyn&reg;: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk. Take early in day to avoid nocturia. Take the last dose of multiple doses no later than 6 PM unless instructed otherwise.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension; treatment of edema in heart failure and nephrotic syndrome, impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metolazone may be confused with metaxalone, methadone, methazolamide, methimazole, methotrexate, metoclopramide, metoprolol, minoxidil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zaroxolyn&reg; may be confused with Zarontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain/discomfort, necrotizing angiitis, orthostatic hypotension, palpitation, syncope, venous thrombosis, vertigo, volume depletion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, depression, dizziness, drowsiness, fatigue, headache, lightheadedness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Petechiae, photosensitivity, pruritus, purpura, rash, skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout attacks, hypercalcemia, hyperglycemia, hyperuricemia, hypochloremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal pain, anorexia, constipation, diarrhea, epigastric distress, nausea, pancreatitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic/hypoplastic anemia, hemoconcentration, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Joint pain, muscle cramps/spasm, neuropathy, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, glucosuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metolazone, any component of the formulation, other thiazides, and sulfonamide derivatives; anuria; hepatic coma; pregnancy (expert analysis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid in severe renal disease (ineffective).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Furosemide:  Large or prolonged fluid and electrolyte losses may occur with concomitant furosemide administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May potentiate hypotensive effect of metazolone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of metolazone. Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of metolazone.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Metolazone crosses the placenta and appears in cord blood. Hypoglycemia, hypokalemia, hyponatremia, jaundice, and thrombocytopenia are reported as complications to the fetus or newborn following maternal use of thiazide diuretics.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F195694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after breakfast; may require potassium supplementation",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metolazone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $132.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $150.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $180.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zaroxolyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $332.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $378.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes (potassium, sodium, chloride, bicarbonate), renal function, blood pressure (standing, sitting/supine)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Barolyn (FI);",
"     </li>",
"     <li>",
"      Birobin (AT);",
"     </li>",
"     <li>",
"      Diondel (ES);",
"     </li>",
"     <li>",
"      Diulo (AU, PT);",
"     </li>",
"     <li>",
"      Metenix 5 (GB, GR, IE, SG);",
"     </li>",
"     <li>",
"      Metolaz (IN);",
"     </li>",
"     <li>",
"      Metos (KP);",
"     </li>",
"     <li>",
"      Mycros (TW);",
"     </li>",
"     <li>",
"      Mykrox (TW);",
"     </li>",
"     <li>",
"      Mykyo (TW);",
"     </li>",
"     <li>",
"      Oldren (AR);",
"     </li>",
"     <li>",
"      Pavedal (CN);",
"     </li>",
"     <li>",
"      Rixia (TW);",
"     </li>",
"     <li>",
"      Zaroxolyn (CH, DE, HK, IL, IT, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as, potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: ~60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%); bile (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arnold WC, &ldquo;Efficacy of Metolazone and Furosemide in Children With Furosemide-Resistant Edema,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1984, 74(5):872-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/32/1542/abstract-text/6493882/pubmed\" id=\"6493882\" target=\"_blank\">",
"        6493882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Channer KS, McLean KA, Lawson-Matthew P, et al, &ldquo;Combination Diuretic Treatment in Severe Heart Failure: A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Br Heart J",
"      </i>",
"      , 1994, 71(2):146-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/32/1542/abstract-text/8130022/pubmed\" id=\"8130022\" target=\"_blank\">",
"        8130022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/32/1542/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/32/1542/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, &ldquo;The Pharmacology and Therapeutics of Diuretics in the Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1990, 37(2):463-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/32/1542/abstract-text/2184406/pubmed\" id=\"2184406\" target=\"_blank\">",
"        2184406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9644 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1542=[""].join("\n");
var outline_f1_32_1542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195707\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195708\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195738\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195711\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195712\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195713\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195668\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195686\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195685\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195746\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195736\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195690\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195672\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299705\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195704\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195717\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195694\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195693\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195680\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038678\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195671\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195689\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/46/5861?source=related_link\">",
"      Metolazone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/50/30501?source=related_link\">",
"      Metolazone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_32_1543="Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy";
var content_f1_32_1543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1543/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/32/1543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antihypertensive agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    , calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , have a good safety profile for use in pregnant women. In contrast, animal and human data suggest that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with increased risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/1-10\">",
"     1-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the known adverse effects of ACE inhibition and angiotensin II receptor blockers (ARBs) in pregnancy. The treatment of hypertension in pregnant and breastfeeding women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF ADVERSE FETAL/NEONATAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant fetal risks associated with the use of ACE inhibitors and ARBs at all stages of pregnancy.",
"   </p>",
"   <p>",
"    A systematic review of pregnancy outcome following exposure to ACE inhibitors or ARBs included 72 reports and 186 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/11\">",
"     11",
"    </a>",
"    ]. Approximately one-third of the cases involved first trimester exposure. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse fetal and neonatal outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oligohydramnios: 55 (30 percent)",
"     </li>",
"     <li>",
"      Anuria: 51 (27 percent)",
"     </li>",
"     <li>",
"      Renal",
"      <span class=\"nowrap\">",
"       failure/dialysis:",
"      </span>",
"      62 (33 percent)",
"     </li>",
"     <li>",
"      Hypotension: 30 (16 percent)",
"     </li>",
"     <li>",
"      Pulmonary hypoplasia: 17 (9 percent)",
"     </li>",
"     <li>",
"      Respiratory distress syndrome: 41 (22 percent)",
"     </li>",
"     <li>",
"      Persistent patent ductus: 13 (7 percent)",
"     </li>",
"     <li>",
"      Hypocalvaria: 32 (17 percent)",
"     </li>",
"     <li>",
"      Limb defect: 31 (17 percent)",
"     </li>",
"     <li>",
"      Fetal growth restriction: 29 (16 percent)",
"     </li>",
"     <li>",
"      Cerebral complications: 12 (6 percent)",
"     </li>",
"     <li>",
"      Miscarriage or perinatal death: 46 (25 percent)",
"     </li>",
"     <li>",
"      Normal (ie, no evidence of renin-angiotensin system blockade): 70 (38 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of renin-angiotensin system blockade in neonates were significantly more common after in utero exposure to ARBs than after exposure to ACE inhibitors, and with exposure in the second",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      third trimester or entire pregnancy.",
"     </li>",
"     <li>",
"      Among the 26 children who survived and were followed for &gt;6 months, 13 (50 percent) had a normal outcome, 11 (42 percent) had mild renal insufficiency, and 2 (8 percent) had severe renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     First trimester exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 epidemiologic study first suggested that ACE inhibitors are not safe in early pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/2\">",
"     2",
"    </a>",
"    ]. This study evaluated Medicaid data on 29,507 infants born in Tennessee between 1985 and 2000. Of these infants, 209 were exposed to ACE inhibitors in the first trimester only, 202 were exposed to other antihypertensive agents in the first trimester, and the remainder had no exposure to antihypertensive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/2\">",
"     2",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of major congenital malformations was significantly increased among infants exposed to ACE inhibitors in the first trimester compared to those with no exposure to antihypertensive drugs (risk ratio [RR] 2.7; 95% CI 1.7-4.3; malformation rate: 7.1 versus 2.6 percent of births).",
"     </li>",
"     <li>",
"      The congenital anomalies with the highest relative risk were cardiovascular malformations (RR 3.7; malformation rate: 2.9 versus 0.8 percent of births) and central nervous system (CNS) malformations (RR 4.4; malformation rate: 1.5 versus 0.3 percent of births); however, the number of affected infants was small.",
"      <br/>",
"      <br/>",
"      The cardiovascular anomalies consisted of atrial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventricular septal defect (seven infants) and patent ductus arteriosus (two infants). The three cases of CNS malformation consisted of one infant with spina bifida, one infant with microcephaly and an undefined eye anomaly, and one infant with coloboma (not a true CNS defect).",
"     </li>",
"     <li>",
"      Exposure to non-ACE inhibitor, non-ARB antihypertensive drugs in the first trimester was not associated with a significant increase in risk of malformations (RR 0.66; 95% CI 0.25-1.75).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strengths of this study are that the authors attempted to adjust for confounders, such as maternal diabetes mellitus and difficult to control hypertension, and that major congenital malformations were identified from linked vital records and hospitalization claims during the first year of life and confirmed through medical record review. However, some potentially important confounders, such as differences between groups in maternal age and rate of obesity, were not taken into account, and some women with diabetes were not identified because they were managed by diet alone. Importantly, there was no attempt to determine the frequency of congenital anomalies in pregnancies that miscarried or were terminated.",
"   </p>",
"   <p>",
"    This study does not prove a cause-and-effect relationship between ACE inhibitors and development of congenital anomalies, and the observed association has not been confirmed. Subsequently, several studies have questioned the relationship between first trimester exposure to ACE inhibitors and congenital anomalies. A case control analysis of the National Birth Defects Prevention Study reported that any antihypertensive medication use may be associated with an increased risk of having an infant with cardiovascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar conclusions regarding any hypertensive exposure and increased risk were made by an analysis of the Swedish Medical Birth Register [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/13\">",
"     13",
"    </a>",
"    ]. Most recently, data from a large, population based cohort study based on information from more than 465,000 mother-infant pairs in the Kaiser Permanente Northern California system suggested that hypertension, rather than ACE inhibitors or other antihypertensive therapies, is a risk factor for development of congenital anomalies.",
"   </p>",
"   <p>",
"    This population based, retrospective cohort study used automated clinical and pharmacy databases to examine the reported association between use of ACE inhibitors during pregnancy and risk of malformations in offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/14\">",
"     14",
"    </a>",
"    ]. This study included 755 mother-infant pairs exposed to ACE inhibitors; 17,507 mother-infant pairs exposed to other antihypertensive agents; 31,274 mother-infant pairs with untreated maternal hypertension; and 416,218 mother-infant pairs without hypertension or exposure to antihypertensive drugs. Compared with pregnant women without hypertension",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertensive pregnant women had about a 20 percent increase in risk of delivering a liveborn infant with a congenital malformation regardless of whether they were managed with ACE inhibitors, other antihypertensive drugs, or no treatment. The absolute risk and odds of any malformation by group were: normal controls (5.4 percent; referent), ACE inhibitor exposure",
"      <span class=\"nowrap\">",
"       (34/400",
"      </span>",
"      infants, 8.5 percent; OR 1.20, 95% CI 0.84-1.72), other antihypertensive drug exposure",
"      <span class=\"nowrap\">",
"       (79/1141",
"      </span>",
"      infants, 6.9 percent; OR 1.22, 95% CI 0.97-1.54), untreated hypertension",
"      <span class=\"nowrap\">",
"       (2247/31274,",
"      </span>",
"      7.2 percent; OR 1.25, 95% CI 1.19-1.31).",
"     </li>",
"     <li>",
"      Hypertensive pregnant women had 40 to 50 percent increase in risk of delivering a liveborn infant with congenital heart defect regardless of whether they were managed with ACE inhibitors, other antihypertensive drugs, or no treatment. The absolute risk and odds of congenital heart disease by group were: normal controls (1.6 percent; referent), ACE inhibitor exposure",
"      <span class=\"nowrap\">",
"       (15/381",
"      </span>",
"      infants, 3.9 percent; OR 1.54, 95% CI 0.90-2.62), other antihypertensive drug exposure",
"      <span class=\"nowrap\">",
"       (28/1090",
"      </span>",
"      infants, 2.6 percent; OR 1.52, 95% CI 1.04-2.21), untreated hypertension",
"      <span class=\"nowrap\">",
"       (708/29735",
"      </span>",
"      infants, 2.4 percent; OR 1.41, 95% CI 1.30-1.53).",
"     </li>",
"     <li>",
"      Women treated with ACE inhibitors or other antihypertensive therapies were not at increased risk of delivering a liveborn infant with a neural tube defect, while those with untreated hypertension were at increased risk. The absolute risk and odds of neural tube defects by group were: normal controls (0.6 percent; referent), ACE inhibitor exposure",
"      <span class=\"nowrap\">",
"       (2/368",
"      </span>",
"      infants, 0.5 percent; OR 0.59, 95% CI 0.14-2.39), other antihypertensive drug exposure",
"      <span class=\"nowrap\">",
"       (9/1071",
"      </span>",
"      infants, 0.8 percent; OR 1.26, 95% CI 0.65-2.44), untreated hypertension",
"      <span class=\"nowrap\">",
"       (281/29,308",
"      </span>",
"      infants, 1.0 percent; OR 1.43, 95% CI 1.26-1.62). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study population was much larger and more diverse than the population studied in Tennessee. Additional strengths of this study are that it included a control population of untreated hypertensive women and adjusted for pre-existing diabetes, maternal age, ethnicity, parity, and maternal weight. Some limitations were that drug exposure was based on filled prescriptions rather than assessing women&rsquo;s compliance in taking the drugs and there was no information on the characteristics of women with treated versus untreated hypertension.",
"   </p>",
"   <p>",
"    A limitation of both the Tennessee and California studies is that malformations among miscarriages, pregnancy terminations, and stillbirths were not assessed.",
"   </p>",
"   <p>",
"    Although recent well conducted observational research, including the systematic review and meta-analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/11\">",
"     11",
"    </a>",
"    ], has questioned the association between first trimester ACE inhibitor use and congenital (particularly cardiac) abnormalities, given the proven risks of exposure in second and third trimester, we continue to recommend that these drugs be avoided throughout pregnancy.",
"   </p>",
"   <p>",
"    Although there is less information about the risk of congenital malformations associated with first trimester exposure to ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], the available literature suggests that these agents have the same risks as ACE inhibitors; thus similar concerns apply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Second and third trimester exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systematic review and meta-analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/11\">",
"     11",
"    </a>",
"    ] provides good evidence that second and third trimester exposure to ACE inhibitors and ARBs is associated with serious adverse",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    effects.",
"   </p>",
"   <p>",
"    The most common problems are related to impaired",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    renal function, which results in oligohydramnios during pregnancy (amniotic fluid is largely derived from the fetal kidneys), and anuria and renal failure after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/1,6-9\">",
"     1,6-9",
"    </a>",
"    ]. Oligohydramnios increases the risk of umbilical cord compression and, in turn, fetal death. Severe oligohydramnios can lead to poor pulmonary development (pulmonary hypoplasia) and development of limb contractures and skeletal deformations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link&amp;anchor=H11#H11\">",
"     \"Oligohydramnios\", section on 'Prognosis and management'",
"    </a>",
"    .) Hypocalvaria, retinopathy, and prolonged neonatal hypotension have also been observed with second or third trimester ACE inhibitor exposure.",
"   </p>",
"   <p>",
"    Other observed adverse effects, such as nonreassuring findings on antepartum fetal assessment, spontaneous or medically-indicated preterm birth, and low birth",
"    <span class=\"nowrap\">",
"     weight/growth",
"    </span>",
"    restriction, are difficult to evaluate since the underlying maternal conditions for which ACE inhibitors and ARBs are commonly prescribed (eg, hypertension, renal insufficiency, heart failure) are also associated with these complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161897\">",
"    <span class=\"h2\">",
"     Exposure through breast milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors are transferred into breast milk, but have very low levels in the milk.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     Captopril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    have been reviewed by the American Academy of Pediatrics and are compatible for use in lactation. However, newborns may be more susceptible to the hemodynamic effects of these drugs, such as hypotension, and sequelae, such as oliguria and seizures. Therefore, the hemodynamic status of the infant should be taken into account when deciding whether women taking these drugs should breastfeed.",
"    <br/>",
"    <br/>",
"    There is no information on the use of ARBs during breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27568614\">",
"    <span class=\"h1\">",
"     HYPOTHESES FOR PATHOGENESIS OF ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse fetal renal effects of ACE inhibitors and ARBs are likely consequences of their ability to cross the placenta and interfere with fetal renal hemodynamics. Because the fetal circulation is characterized by low perfusion pressures, high angiotensin II levels are needed to maintain the GFR. ACE inhibitors and ARBs rapidly reduce angiotensin II levels, thereby reducing intraglomerular pressure and inducing a decline in GFR, which is reflected by oligohydramnios in utero and anuria after delivery. In animal studies, loss of function mutations in renin-angiotensin system (RAS) genes similarly results in abnormal renal development, reduced fetal diuresis, and oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental evidence also suggests that angiotensin II may participate in the regulation of uteroplacental blood flow, perhaps by stimulating vascular production of vasodilator prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, inhibition of angiotensin II could lead to fetal growth restriction. Angiotensin II may also play a direct role in fetal growth and development, particularly of the fetal kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Retinopathy and hypocalvaria in exposed fetuses has been attributed to drug-related reductions in normal retinal and cranial vascularization during fetal development rather than to oxygen toxicity or deformation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these effects, AT",
"    <sub>",
"     1",
"    </sub>",
"    receptor blockade results in the disinhibition of renin release by angiotensin II and increased formation of all angiotensin peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/21\">",
"     21",
"    </a>",
"    ]. These peptides could activate the AT",
"    <sub>",
"     2",
"    </sub>",
"    receptor, which is highly expressed in the fetus. However, the consequences of this effect are unknown. A brief review of the actions of angiotensin II on glomerular hemodynamics can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS OF SYMPTOMATIC NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function may appear to improve over time in infants, but the long-term outcome in survivors has not been well described. Three reports including a total of five children with in utero exposure to ACE inhibitors associated with transient acute renal failure in the neonatal period have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Four of these five neonates developed mild renal insufficiency during childhood. Another report of a child exposed to an ARB during pregnancy described chronic kidney disease and development delay at 34 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/25\">",
"     25",
"    </a>",
"    ]. A series of seven cases of ARB exposure during pregnancy reported several cases of irreversible neonatal renal failure and death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1543/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are sparse, they suggest that renal function should be monitored in children with a history of transient neonatal renal failure related to exposure to ACE inhibitors and ARBs in utero.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1161932\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT IN WOMEN OF CHILDBEARING POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The avoidance of ACE inhibitors and ARBs at any stage of pregnancy is justified by the strength of the observed associations and by the availability of other agents that are effective for blood pressure control. As a result, all women in childbearing years who are being considered for therapy with ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs should be counseled about the potential fetal risks associated with these agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest avoidance of ACE inhibitors or ARBs in women of childbearing age for whom there are reasonable alternative anti-hypertensive drugs that would be safer for the fetus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of hypertension in pregnant and postpartum women\", section on 'Chronic (preexistent) hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When effective alternatives are not clearly available (eg, prevention of progression of proteinuric chronic kidney disease), the woman should be counseled about the importance of consistent and correct use of effective contraception. The Centers for Disease Control and Prevention have published evidenced-based recommendations for options of hormonal contraceptives in women with cardiovascular disease (",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pregnancy is not contraindicated. For women planning pregnancy, very early detection of pregnancy is important to minimize embryonic exposure to ACE inhibitors or ARBs (",
"      <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"       figure 1",
"      </a>",
"      ). If her menstrual period is delayed by more than two days, the woman should discontinue her ACE inhibitor or ARB, undergo a pregnancy test (blood is more sensitive than urine in very early pregnancy), and consult her physician. The diagnosis of very early pregnancy can be challenging, given the normal variation in menstrual cycle length and the frequency of irregular menstrual cycles. A negative pregnancy test should be repeated in a few days if menses have not resumed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      .) Abrupt cessation of an ACE inhibitor or ARB does not result in rebound hypertension.",
"     </li>",
"     <li>",
"      ACE inhibitors or ARBs should be discontinued immediately in women who present in early pregnancy on these drugs. An alternate agent is initiated, if necessary. We avoid use of all drugs which block the renin angiotensin system during pregnancy, including renin inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Women with diabetes with micro- or macro-proteinuria who are planning",
"      <span class=\"nowrap\">",
"       pregnancy/pregnant",
"      </span>",
"      may be switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      since these drugs have been reported to reduce proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of diabetic nephropathy\", section on 'Other antihypertensive drugs and combinations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162130\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are significant fetal risks associated with the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in all stages of pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of adverse fetal/neonatal effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First trimester exposure to ACE inhibitors (and probably ARBs) may increase the risk of cardiovascular and central nervous system malformations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'First trimester exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the second and third trimesters, ACE inhibitors can interfere with fetal renal hemodynamics, resulting in a fall in GFR. Oligohydramnios may occur due to decreased fetal urine production; possible consequences include fetal pulmonary hypoplasia, deformational abnormalities, and death. After birth, the neonate may have renal failure, which usually improves over time. The long-term outcome in survivors has not been well described. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Second and third trimester exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1162115\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest avoidance of ACE inhibitors or ARBs in women of childbearing age for whom there are other antihypertensive drugs that would be safer for the fetus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When effective alternatives are not clearly available (eg, prevention of progression of proteinuric or microalbuminuric diabetic kidney disease), the woman should be counseled about early detection of pregnancy. In these situations, we suggest instructing women to discontinue the ACE inhibitor or ARB if the menstrual period is delayed by more than two days, to have a sensitive pregnancy test, and to consult with their physician.",
"     </li>",
"     <li>",
"      We recommend immediate discontinuation of an ACE inhibitor or ARB in women who present in early pregnancy, with substitution of an alternate agent if necessary (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We avoid use of all drugs that block the renin angiotensin system during pregnancy, including renin inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1161932\">",
"       'Approach to treatment in women of childbearing potential'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/1\">",
"      Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/2\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/3\">",
"      Broughton Pipkin F, Symonds EM, Turner SR. The effect of captopril (SQ14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol 1982; 323:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/4\">",
"      Keith IM, Will JA, Weir EK. Captopril: association with fetal death and pulmonary vascular changes in the rabbit. Proc Soc Exp Biol Med 1982; 170:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/5\">",
"      Ferris TF, Weir EK. Effect of captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit. J Clin Invest 1983; 71:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/6\">",
"      Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 1988; 108:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/7\">",
"      Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/8\">",
"      Pryde PG, Sedman AB, Nugent CE, Barr M Jr. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993; 3:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/9\">",
"      Tabacova S, Little R, Tsong Y, et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003; 12:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/10\">",
"      H&uuml;nseler C, Paneitz A, Friedrich D, et al. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr 2011; 223:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/11\">",
"      Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/12\">",
"      Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/13\">",
"      Lennest&aring;l R, Otterblad Olausson P, K&auml;ll&eacute;n B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/14\">",
"      Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/15\">",
"      Vel&aacute;zquez-Armenta EY, Han JY, Choi JS, et al. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007; 26:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/16\">",
"      Karthikeyan VJ, Ferner RE, Baghdadi S, et al. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011; 29:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/17\">",
"      Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int 2010; 77:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/18\">",
"      Millan MA, Carvallo P, Izumi S, et al. Novel sites of expression of functional angiotensin II receptors in the late gestation fetus. Science 1989; 244:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/19\">",
"      Guron G, Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000; 18:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/20\">",
"      H&aring;rd AL, Wennerholm UB, Niklasson A, Hellstr&ouml;m A. Severe ROP in twins after blockage of the renin-angiotensin system during gestation. Acta Paediatr 2008; 97:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/21\">",
"      Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/22\">",
"      Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 2005; 39:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/23\">",
"      Guron G, M&ouml;lne J, Swerkersson S, et al. A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant 2006; 21:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/24\">",
"      Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 2007; 92:F402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1543/abstract/25\">",
"      Simonetti GD, Baumann T, Pachlopnik JM, et al. Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan. Pediatr Nephrol 2006; 21:1329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4789 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1543=[""].join("\n");
var outline_f1_32_1543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF ADVERSE FETAL/NEONATAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      First trimester exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Second and third trimester exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1161897\">",
"      Exposure through breast milk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27568614\">",
"      HYPOTHESES FOR PATHOGENESIS OF ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LONG-TERM PROGNOSIS OF SYMPTOMATIC NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1161932\">",
"      APPROACH TO TREATMENT IN WOMEN OF CHILDBEARING POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1162130\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1162115\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4789|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 1\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_32_1544="Comparing child and parent head circumference";
var content_f1_32_1544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 656px\">",
"   <div class=\"ttl\">",
"    Comparing child and parent head circumference",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 636px; height: 812px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It is helpful to simultaneously plot the child's and parents' occipitofrontal circumference (OFC) measurements to compare the percentile or standard deviation. For most normal children, the child's OFC percentile is between that of the parents. In the example above, the child's OFC is certainly small relative to that of his parents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Rollins JD, Collins JS, Holden KR. United States head circumference growth reference charts: birth to 21 years. J Pediatr 2010; 156:907. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1544=[""].join("\n");
var outline_f1_32_1544=null;
var title_f1_32_1545="Testosterone treatment of male hypogonadism";
var content_f1_32_1545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Testosterone treatment of male hypogonadism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1545/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/32/1545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism in a male refers to a decrease in either of the two major functions of the testes: sperm production or testosterone production. These abnormalities can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). The use of testosterone to treat male hypogonadism, primary or secondary, is reviewed here. The clinical manifestations and diagnosis of male hypogonadism are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles should guide testosterone therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testosterone should be administered",
"      <strong>",
"       only to a man who is hypogonadal",
"      </strong>",
"      , as evidenced by clinical symptoms and signs consistent with androgen deficiency and a distinctly subnormal serum testosterone concentration. In comparison, increasing the serum testosterone concentration in a man who has symptoms suggestive of hypogonadism but whose testosterone concentration is already normal will not relieve those symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"       \"Clinical features and diagnosis of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testosterone can be replaced satisfactorily whether the testosterone deficiency is due to primary or secondary hypogonadism.",
"     </li>",
"     <li>",
"      The principal goal of testosterone therapy is to restore the serum testosterone concentration to the normal range. It is not yet known if restoring the normal circadian rhythm of testosterone is important. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=see_link\">",
"       \"Male reproductive physiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of testosterone replacement to treat the decline in serum testosterone concentration that occurs with increasing frequency above age 60 in the absence of identifiable pituitary or hypothalamic disease is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"       \"Overview of testosterone deficiency in elderly men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TESTOSTERONE PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing among the different testosterone preparations requires an understanding of their pharmacokinetics. Native testosterone is absorbed well from the intestine, but it is metabolized so rapidly by the liver that it is virtually impossible to maintain a normal serum testosterone concentration in a hypogonadal man with oral testosterone. The solutions to this problem that have been developed over many years involve modifying the testosterone molecule, changing the method of testosterone delivery, or both. The following testosterone preparations are currently available or are under development for treating testosterone deficiency:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alkylated androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decades ago, investigators discovered that adding an alkyl group in the 17-alpha position of the testosterone molecule retarded its catabolism by the liver (",
"    <a class=\"graphic graphic_figure graphicRef53955 \" href=\"UTD.htm?15/21/15699\">",
"     figure 1",
"    </a>",
"    ). Since that time, several 17-alkylated androgens (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3652?source=see_link\">",
"     methyltestosterone",
"    </a>",
"    ) have been available for oral use. Many endocrinologists who treat male hypogonadism think that these preparations are not fully effective in producing virilization, although no studies have tested these observations. In addition, several reports have described hepatic side effects with these preparations, including cholestatic jaundice, a hepatic cystic disease called peliosis hepatis, and hepatoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. For both of these reasons, and because better preparations are available, the 17-alkylated androgens should generally",
"    <strong>",
"     not be used",
"    </strong>",
"    to treat testosterone deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Testosterone esters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone enanthate and testosterone cypionate are esters of testosterone that have been used for many years for the treatment of testosterone deficiency. The rationale for their use is that esterification of a lipophilic fatty acid to the 17-beta hydroxyl group of testosterone (",
"    <a class=\"graphic graphic_figure graphicRef53955 \" href=\"UTD.htm?15/21/15699\">",
"     figure 1",
"    </a>",
"    ) makes testosterone even more lipophilic than the native molecule. Intramuscular injection of testosterone esters results in their storage in and gradual release from the oil-based vehicle in which they are administered, thereby prolonging the presence of testosterone in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic characteristics of testosterone enanthate are relatively well described. In one report, for example, 100 mg of testosterone enanthate was administered once a week for 12 weeks to 12 men with primary hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/8\">",
"     8",
"    </a>",
"    ]. The mean serum testosterone concentration increased to slightly higher than the upper limit of normal one to two days after the injection and gradually decreased to the mid-normal range by the time of the next injection.",
"   </p>",
"   <p>",
"    When the dose of testosterone was increased to 200 mg in an attempt to prolong the dosing interval to every two weeks, the peak serum testosterone concentration increased further, and the nadir, just before the next injection, decreased to the low-normal range (",
"    <a class=\"graphic graphic_figure graphicRef74011 \" href=\"UTD.htm?12/62/13295\">",
"     figure 2",
"    </a>",
"    ). Regimens of 300 mg every three weeks and 400 mg every four weeks increased the peaks and decreased the nadirs further.",
"   </p>",
"   <p>",
"    The serum concentrations of luteinizing hormone (LH), which were initially above normal in all the men, decreased gradually after initiation of the 100",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    regimen, reaching the normal range by six to eight weeks and remaining in the normal range thereafter. Serum LH concentrations also decreased to normal with the 200 mg per two week regimen, barely to normal with the 300 mg per three week regimen, and remained supranormal with the 400 mg per four week regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that testosterone enanthate doses from 100 mg per week to 300 mg per three weeks are biologically effective, but that 400 mg per four weeks is not. Less information is available for testosterone cypionate, but the few studies that have been performed suggest that its characteristics are similar to those of testosterone enanthate.",
"   </p>",
"   <p>",
"    An advantage of testosterone enanthate and cypionate over other testosterone preparations is that they are biologically effective in initiating and maintaining normal virilization in all hypogonadal men. Another advantage to some men is freedom from daily administration. The disadvantages are the need for deep intramuscular administration of an oily solution every one to three weeks and fluctuations in the serum testosterone concentration, which result in fluctuations in energy, mood, and libido in many patients. These fluctuations are more pronounced as the dosing interval is increased.",
"   </p>",
"   <p>",
"    An intramuscular formulation of another ester of testosterone, testosterone undecanoate, has been approved under the trade name Nebido in several countries for treatment of hypogonadism. The prescribing information from the manufacturer recommends a dose of 1000 mg administered as a deep IM injection, with a second dose six weeks after the first and subsequent doses every 10 to 14 weeks. One study demonstrated that 1000 mg every three months maintained the mean serum testosterone concentration within the normal range for 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/9\">",
"     9",
"    </a>",
"    ]. An oral formulation of this ester is also available in some countries, but it does not keep the serum testosterone concentration normal in hypogonadal men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transdermal/topical delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal delivery of testosterone first became available in 1994 with the introduction of a scrotal patch. Since then, body patches and gels have also become available, but the scrotal patch is no longer available in the United States. The major advantage of transdermal administration is maintenance of relatively stable serum testosterone concentrations, resulting in maintenance of relatively stable energy, mood, and libido.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;One patch, Androderm, is available in some countries. It is no longer available in the UK. Androderm relies upon chemical means to increase the absorption of testosterone across nongenital skin, and it is meant to be worn on the arm or torso. It delivers approximately 5 mg of testosterone per 24 hours and results in normal serum testosterone concentrations in the majority of hypogonadal men (",
"    <a class=\"graphic graphic_figure graphicRef74011 \" href=\"UTD.htm?12/62/13295\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Anecdotal reports suggest that as many as one-third of men who try this preparation cannot continue it because of severe skin rash. A matrix transdermal testosterone patch is available in countries outside the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Testosterone gels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four testosterone gels are available: AndroGel, Testim, Fortesta, and Axiron.",
"   </p>",
"   <p>",
"    AndroGel is supplied in both 1 percent and 1.62 percent concentrations. The 1 percent concentration was the first to become available. It is still available in 2.5 g and 5.0 g packets, which contain 25 mg and 50 mg of testosterone, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], and a metered-dose pump that delivers 1.25 g of gel (containing 12.5 mg of testosterone) per pump depression. When this preparation is applied to the skin once a day in doses of 5 to 10 g (delivering 50 to 100 mg of testosterone), the serum testosterone concentrations usually reach the normal male range within a month and remain steady throughout 24 hours (",
"    <a class=\"graphic graphic_figure graphicRef74011 \" href=\"UTD.htm?12/62/13295\">",
"     figure 2",
"    </a>",
"    ). The serum concentrations of testosterone throughout the 24 hours from one application to the next are similar at one, three, and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/17\">",
"     17",
"    </a>",
"    ]. Occasional local skin irritation occurs but usually does not necessitate discontinuation of therapy.",
"   </p>",
"   <p>",
"    The 1.62 percent preparation of AndroGel was introduced later and is available in pump bottles. Each depression of the pump yields 1.25 g of gel containing 20.25 mg of testosterone. A study comparing the bioavailability of this preparation at different application sites demonstrated 30 percent lower availability when it was applied to the abdomen than to the arms and shoulders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/18\">",
"     18",
"    </a>",
"    ]. In another study, administration of 1.25 to 5.0 g a day to men with slightly low serum testosterone concentrations increased the values to within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testim (1 percent testosterone gel) is supplied in tubes containing doses of 5 g and 10 g, which contain 50 mg and 100 mg of testosterone, respectively, and when applied daily, usually result in normal serum concentrations of testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/20\">",
"     20",
"    </a>",
"    ]. Anecdotal reports suggest that this preparation gives an odor.",
"   </p>",
"   <p>",
"    Fortesta (2 percent testosterone gel) is also supplied in a metered-dose pump, with each pump depression delivering 0.5 g of gel (containing 10 mg of testosterone) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/21\">",
"     21",
"    </a>",
"    ]. The recommended starting dose is 40 mg, applied to the front and inner thighs, and adjusted to a minimum of 10 mg and a maximum of 70 mg, as determined by the serum testosterone concentration. A study in hypogonadal men showed that after 90 days of daily use, the mean serum testosterone concentration before gel application was in the low end of the normal range, after application reached a peak in the mid-normal range in about four hours, and fell to the baseline level 12 hours after application [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Axiron (2 percent testosterone solution) is a solution of testosterone that also comes in a metered-dose pump with applicator. Each depression yields 30 mg of testosterone. The package insert suggests a starting dose of 30 mg applied to each axilla once a day and adjustment of the dose as low as 30 mg and as high as 120 mg once a day, as judged by the serum testosterone concentration. A study in hypogonadal men treated with 30 to 90 mg of this preparation increased the mean serum testosterone concentration to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69695579\">",
"    <span class=\"h2\">",
"     Other preparations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Buccal tablet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A buccal tablet (Striant SR), 30 mg, is applied twice a day and adheres to a depression in the gum above the upper incisors. It releases testosterone across the buccal mucosa into the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217495\">",
"    <span class=\"h3\">",
"     Testosterone pellet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subcutaneous testosterone pellet (Testopel) is available. The manufacturer recommends three to six 75 mg testosterone pellets every three to six months. The pellets are implanted into the subdermal fat of the buttocks, lower abdominal wall or thigh with a trocar under sterile conditions using a local anesthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/25\">",
"     25",
"    </a>",
"    ]. Adverse events include pellet extrusion, infection, and fibrosis. Because of the need for surgery to insert them and the limited data on the serum testosterone concentrations during treatment, we do not routinely recommend this preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Human chorionic gonadotropin (hCG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This preparation, while not an androgen, stimulates the testes to make testosterone and is especially useful in stimulating both testosterone and sperm production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treated with testosterone should be monitored to determine that normal serum testosterone concentrations are being achieved. Monitoring should be done two to three months after initiation of treatment and after changing a dose. When the dose appears to be stable, monitoring over 6 to 12 months should suffice. They should also be monitored for both desirable and undesirable effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum testosterone concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of serum testosterone measurements varies with the preparation that is used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum testosterone should be measured midway between injections in men who are receiving testosterone enanthate and the value should be mid-normal, eg, 500 to 600",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (20.8 to 24.3",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      The dose should be reduced if higher values are obtained.",
"     </li>",
"     <li>",
"      The serum testosterone can be measured at any time in men who are using any of the transdermal preparations, with the recognition that the peak values occur six to eight hours after application of the patch. The concentrations fluctuate when a gel is used, but not in a predictable way, so at least two measurements should be made at any dose of gel; the time of measurement does not appear to matter. The value should be well within the normal range (400 to 700",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [13.9 to 27.7",
"      <span class=\"nowrap\">",
"       nmol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient has primary hypogonadism, normalization of the serum LH concentration should also be used to judge the adequacy of the testosterone dose, no matter which testosterone preparation is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The desirable effects of testosterone administration include the development or maintenance of secondary sexual characteristics and increases in libido, muscle strength, fat-free mass, and bone density. Undesirable effects related directly to testosterone include acne, prostate disorders (such as benign prostatic hyperplasia symptoms), sleep apnea, and erythrocytosis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Undesirable effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Virilization/sexual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normalization of the serum testosterone concentration should lead to normal virilization in men who are not virilized and maintenance of virilization in those who already are. Men who become hypogonadal in adulthood and are still normally virilized but whose hypogonadism is manifested by a decrease in libido and energy should note a marked improvement in these symptoms. Failure of improvement when the serum testosterone concentration has been restored to normal suggests another cause of the symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Muscle strength/fat-free mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement also leads to substantial improvements in muscle strength and fat-free mass in hypogonadal men. In one report, for example, the administration of 100 mg of testosterone enanthate once a week for 10 weeks to hypogonadal men increased their strength in the bench press by 22 percent, their squat strength by 45 percent, and fat-free mass by 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement improves bone density in male hypogonadism as illustrated in a study of 72 such men receiving testosterone replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/27\">",
"     27",
"    </a>",
"    ]. The increase in bone density averaged 39 percent in the first year of testosterone replacement and eventually reached and was maintained in the normal range. The response was greatest in the first year in previously untreated patients and was most pronounced in those with lowest bone density measurements at baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of osteoporosis in men\", section on 'Testosterone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Undesirable effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone enanthate and the testosterone patch and gels have few side effects unrelated to the action of testosterone. Some of the actions of testosterone itself, while not side effects, are undesirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Puberty-related",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first few months after the initiation of testosterone replacement, some of the undesirable effects of normal puberty, such as acne and gynecomastia, can be seen.",
"     </li>",
"     <li>",
"      When testosterone is first administered to hypogonadal adolescent boys, verbally or physically aggressive behavior may increase [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overtreatment of a boy whose epiphyses have not yet closed can cause premature closure and permanent short stature.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate volumes and serum prostate specific antigen (PSA) increase in response to testosterone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. On average, values increase to those of age-matched eugonadal men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some men, especially those over the age of 50, experience an exacerbation of benign prostatic hyperplasia (BPH), a testosterone-dependent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/33\">",
"     33",
"    </a>",
"    ]. There have been concerns that symptoms, predominantly lower urinary tract symptoms (LUTS) due to urinary outflow obstruction, may increase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in a 2010 meta-analysis of 51 randomized trials of testosterone therapy in men designed to look at the primary endpoints of mortality, cardiovascular events and risk factors, prostate outcomes and erythrocytosis, no significant effects of testosterone were seen on the incidence of prostate cancer, need for prostate biopsy, increase in PSA, or change in lower urinary tract",
"    <span class=\"nowrap\">",
"     symptoms/score",
"    </span>",
"    when compared to the",
"    <span class=\"nowrap\">",
"     placebo/nonintervention",
"    </span>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H221096\">",
"    <span class=\"h4\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because prostate cancer is, at least to some degree, testosterone dependent, it seems theoretically likely that the risk of prostate cancer is less in hypogonadal men than eugonadal men and the risk increases to normal, but not above, when testosterone is replaced. However, no data are available to support or refute this assumption. It seems prudent, nonetheless, to screen hypogonadal men for prostate cancer before beginning testosterone replacement and to monitor them for prostate cancer during treatment, just as one would monitor a eugonadal man. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of testosterone deficiency in elderly men\", section on 'Prostate cancer'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    We agree with the approach outlined by the Endocrine Society&rsquo;s 2010 Clinical Guidelines, and suggest digital rectal examination and measurement of serum PSA before initiating testosterone replacement in men over age 50 years, or over age 40 years if the man has a family history of prostate cancer or is African-American. In men over age 55 years, they also suggest estimating prostate cancer risk using a prostate cancer risk calculator [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H221112\">",
"    <span class=\"h4\">",
"     Men with a history of prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been reports of administering testosterone therapy to hypogonadal men who have been disease-free for two years or more, with undetectable PSA levels after radical prostatectomy for cancer confined to the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/14,36\">",
"     14,36",
"    </a>",
"    ]. However, data are too limited to make a recommendation at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H221104\">",
"    <span class=\"h4\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no reason to think that men who rely on medication to maintain a normal serum testosterone concentration are more likely to develop these conditions than men who produce their own testosterone. Nevertheless, the clinician who prescribes testosterone for a man over age 50 should monitor him as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For BPH, lower urinary tract symptoms should be assessed by the International Prostate Symptom Score (IPSS) (",
"      <a class=\"graphic graphic_table graphicRef81331 \" href=\"UTD.htm?4/5/4189\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/37\">",
"       37",
"      </a>",
"      ]. If warranted by symptoms, the urine flow rate [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/38\">",
"       38",
"      </a>",
"      ] and post-void residual urine in the bladder by ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/39\">",
"       39",
"      </a>",
"      ] should be measured before beginning treatment. If the diagnosis of moderate or severe LUTS (eg, score &gt;19) due to BPH is made, treatment of that condition should be considered before beginning testosterone replacement. Some men will be bothered and want to consider treatment when their symptoms worsen, even if it is &lt;19. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"       \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For prostate cancer, digital rectal examination and measurement of serum PSA should be performed three to six months after initiation of treatment and then once a year. The patient should be referred to a urologist for consideration of a prostate biopsy for any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A prostate nodule that is palpated at any time.",
"     </li>",
"     <li>",
"      The serum PSA concentration (confirmed by a repeat value) rises by more than 1.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in any one-year period.",
"     </li>",
"     <li>",
"      A PSA velocity that is greater than 0.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      per year for two or more years, beginning six months after initiation of testosterone therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/14\">",
"       14",
"      </a>",
"      ]. This recommendation assumes that the patient does not have prostatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"       \"Measurement of prostate specific antigen\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea may be worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/14\">",
"     14",
"    </a>",
"    ]; the clinician should inquire about symptoms, such as excessive daytime sleepiness and witnessed apnea during sleep by a partner. If indicated, polysomnography should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .) Patients whose sleep apnea is well-treated with CPAP may take testosterone treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Erythrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytosis is a common adverse effect of testosterone administration, particularly with testosterone ester injections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. The hematocrit should be measured before initiating testosterone treatment and if it is elevated, the cause should be sought before testosterone treatment is initiated. The hematocrit should be measured again after three to six months, and then yearly. If it increases above the upper limit of normal, a cause should be sought, and if none is found, the dose of testosterone should be decreased or stopped. The hematocrit should be re-evaluated two months after the decrease or discontinuation. If the hematocrit normalizes, a lower dose of testosterone should be continued or restarted. If the hematocrit cannot be kept below the upper limit of normal, even when the serum testosterone concentration is at the low end of the normal range during testosterone treatment, phlebotomy can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Skin irritation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patch, Androderm, often causes skin rashes, some very mild and others quite severe, requiring discontinuation of this treatment. The rash may sometimes be prevented by pretreatment of the skin with a corticosteroid cream [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/41\">",
"     41",
"    </a>",
"    ]. This patch has been taken off the market in some countries. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Patch'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Local skin irritation occasionally occurs with testosterone gels (AndroGel and Testim), but usually is not severe and does not necessitate discontinuation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Secondary exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;With testosterone gels, the possibility of skin transfer to another person is low if the patient follows the package insert directions that include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Washing hands thoroughly after application",
"     </li>",
"     <li>",
"      Avoiding skin contact until the gel has dried completely",
"     </li>",
"     <li>",
"      Keeping the application site covered",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of healthy male volunteers receiving testosterone gel, intense skin contact with a second male volunteer (pretreated with norethisterone [400 mg IM] to suppress endogenous testosterone) did not result in an increase in serum testosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the US Food and Drug Administration has mandated a boxed warning for all testosterone gel products after receiving reports of secondary exposure in eight children ages nine months to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Exposure resulted in penile or clitoral enlargement, premature development of pubic hair, advanced bone age, increased libido, and aggressive behavior, most of which regressed when the child was no longer exposed to testosterone (with the exception of",
"    <span class=\"nowrap\">",
"     penile/clitoral",
"    </span>",
"    enlargement).",
"   </p>",
"   <p>",
"    These complications are extremely rare (eight cases per 1.8 million prescriptions) and, therefore, testosterone gel use should still be considered safe [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/44\">",
"     44",
"    </a>",
"    ]. However, it is extremely important to take precautions to avoid contact transfer of testosterone, eg, by washing hands after application and keeping the application site covered with clothing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1019974\">",
"    <span class=\"h3\">",
"     Suppression of spermatogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of testosterone exogenously suppresses LH secretion and thereby suppresses the high concentration of intratesticular testosterone essential for spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/45\">",
"     45",
"    </a>",
"    ]. In attempts to develop a male contraceptive, high doses of exogenous testosterone alone or replacement doses given together with a gonadotropin-releasing hormone antagonist or a progestin have been shown to suppress spermatogenesis markedly in normal men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link&amp;anchor=H878176#H878176\">",
"     \"Overview of contraception\", section on 'Contraception for men'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the effect of replacement doses of testosterone in men with mild degrees of hypogonadism who still have some degree of spermatogenesis has not been studied, hypogonadal men who are being considered for testosterone replacement should be told of the suppressive effect of testosterone on spermatogenesis and asked if they desire fertility. If they do, other treatments should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=see_link\">",
"     \"Induction of fertility in men with secondary hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Time course of effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of the effects of testosterone replacement is variable. This was illustrated in a three-year study of physiological transdermal testosterone replacement in 18 previously untreated hypogonadal men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/47\">",
"     47",
"    </a>",
"    ]. Increases in fat-free mass, prostate volume, erythropoiesis, energy, and sexual function occurred within the first three to six months. In contrast, the full effect on bone mineral density did not occur until 24 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"       \"Patient information: Androgen replacement in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are consistent with the Endocrine Society Clinical Practice Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1545/abstract/14\">",
"     14",
"    </a>",
"    ]: Testosterone should be administered",
"    <strong>",
"     only to a man who is hypogonadal",
"    </strong>",
"    , as evidenced by clinical symptoms and signs consistent with androgen deficiency and a distinctly subnormal serum testosterone concentration. The principal goal of testosterone therapy is to restore the serum testosterone concentration to the normal range.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of testosterone preparations are available for androgen replacement. We suggest against the use of alkylated androgens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). They are convenient because they are given orally, but they have been associated with adverse liver effects and there are more effective preparations available.",
"     </li>",
"     <li>",
"      We recommend testosterone therapy for symptomatic men with hypogonadism (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We usually suggest transdermal testosterone to most hypogonadal men, especially a gel, because it usually produces normal serum testosterone concentrations, and most patients find it the most convenient. Some men, however, prefer injections of testosterone enanthate because of the freedom from daily application.",
"     </li>",
"     <li>",
"      For some patients, cost may be an issue. In general, the newest preparations (the gels) cost the most, the patch costs somewhat less, and injectable esters cost the least.",
"     </li>",
"     <li>",
"      Men who begin using a transdermal preparation need to be seen two to three months after the initiation of therapy to measure the serum testosterone concentration and evaluate the possibility of undesirable effects. Men who use the transdermal patch or the recommended starting dose of a gel but whose serum testosterone concentration is not high enough, can try wearing two patches or applying higher doses of a gel.",
"     </li>",
"     <li>",
"      For adult hypogonadal men starting testosterone enanthate, we suggest 150 to 200 mg every two weeks, which can be administered either by the patient himself or by someone in the patient's household. The patient should be seen approximately two to three months later and, if he is bothered by fluctuations in energy, mood, or libido, the regimen can be changed to 100 mg once a week or transdermal testosterone can be offered again.",
"     </li>",
"     <li>",
"      Serum testosterone concentrations should be monitored while a patient is being treated. The timing depends upon the preparation used. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men over age 50 years (or over 40 years who have a family history or are African-American) should be screened for prostate cancer before starting therapy and during therapy, as outlined above. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prostate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hematocrit should be measured before initiating testosterone treatment, and if it is elevated, the cause should be sought before testosterone treatment is initiated. The hematocrit should be measured again after three to six months, and then yearly. If it increases above the upper limit of normal, a cause should be sought, and if none is found, the dose of testosterone should be decreased or stopped. The hematocrit should be re-evaluated two months after the decrease or discontinuation. If the hematocrit normalizes, a lower dose of testosterone should be continued or restarted.",
"     </li>",
"     <li>",
"      The role of testosterone replacement to treat the decline in serum testosterone concentration that occurs with increasing frequency above age 60 in the absence identifiable pituitary or hypothalamic disease is uncertain. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"       \"Overview of testosterone deficiency in elderly men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/1\">",
"      Bernstein MS, Hunter RL, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia. N Engl J Med 1971; 284:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/2\">",
"      Johnson FL, Lerner KG, Siegel M, et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972; 2:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/3\">",
"      Henderson JT, Richmond J, Sumerling MD. Androgenic-anabolic steroid therapy and hepatocellular carcinoma. Lancet 1973; 1:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/4\">",
"      Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet 1977; 2:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/5\">",
"      Overly WL, Dankoff JA, Wang BK, Singh UD. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med 1984; 100:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/6\">",
"      Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999; 140:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/7\">",
"      Fujioka M, Shinohara Y, Baba S, et al. Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 1986; 63:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/8\">",
"      Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/9\">",
"      Schubert M, Minnemann T, H&uuml;bler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89:5429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/10\">",
"      Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/11\">",
"      Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. J Clin Endocrinol Metab 1996; 81:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/12\">",
"      Brocks DR, Meikle AW, Boike SC, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol 1996; 36:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/13\">",
"      Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84:3469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/14\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/15\">",
"      Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000; 85:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/16\">",
"      Androgel. Med Lett Drugs Ther 2000; 42:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/17\">",
"      Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85:4500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/18\">",
"      Miller J, Britto M, Fitzpatrick S, et al. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism. Endocr Pract 2011; 17:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/19\">",
"      Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011; 8:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/20\">",
"      McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/21\">",
"      A new testosterone gel (fortesta) for hypogonadism. Med Lett Drugs Ther 2011; 53:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/22\">",
"      Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl 2012; 33:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/23\">",
"      Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011; 75:836.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter 2003; 45:69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/25\">",
"      Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007; 19:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/26\">",
"      Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/27\">",
"      Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/28\">",
"      Finkelstein JW, Susman EJ, Chinchilli VM, et al. Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents. J Clin Endocrinol Metab 1997; 82:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/29\">",
"      Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/30\">",
"      Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/31\">",
"      Curran MJ, Bihrle W 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/32\">",
"      Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994; 40:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/33\">",
"      Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980; 68:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/34\">",
"      Fern&aacute;ndez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.",
"     </a>",
"    </li>",
"    <li>",
"     file://deb.uthscsa.edu/URORiskCalcPages/calcs.jsp (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/36\">",
"      Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/37\">",
"      Bolognese JA, Kozloff RC, Kunitz SC, et al. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 1992; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/38\">",
"      Drach GW, Layton T, Bottaccini MR. A method of adjustment of male peak urinary flow rate for varying age and volume voided. J Urol 1982; 128:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/39\">",
"      Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982; 20:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/40\">",
"      Calof, OM, Singh, AB, Lee, ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med 2005; 60:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/41\">",
"      Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/42\">",
"      Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 2002; 56:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/43\">",
"      Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. Clin Pediatr (Phila) 2007; 46:540.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release, May 7, 2009. Testosterone gel safety concerns prompt FDA to require label changes, medication guide. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149580.htm (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/45\">",
"      Page ST, Kalhorn TF, Bremner WJ, et al. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl 2007; 28:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/46\">",
"      Liu PY, Swerdloff RS, Anawalt BD, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 2008; 93:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1545/abstract/47\">",
"      Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7461 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1545=[""].join("\n");
var outline_f1_32_1545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TESTOSTERONE PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alkylated androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Testosterone esters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transdermal/topical delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Testosterone gels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69695579\">",
"      Other preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Buccal tablet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H217495\">",
"      - Testosterone pellet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Human chorionic gonadotropin (hCG)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum testosterone concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Virilization/sexual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Muscle strength/fat-free mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Undesirable effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Puberty-related",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Prostate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H221096\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H221112\">",
"      Men with a history of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H221104\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Skin irritation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Secondary exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1019974\">",
"      - Suppression of spermatogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Time course of effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7461|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/21/15699\" title=\"figure 1\">",
"      Testosterone preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/62/13295\" title=\"figure 2\">",
"      Serum T conc 3 preps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/5/4189\" title=\"table 1\">",
"      AUA Urinary Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23510?source=related_link\">",
"      Induction of fertility in men with secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31800?source=related_link\">",
"      Male reproductive physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_32_1546="Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment";
var content_f1_32_1546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Charles W Nager, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Jasmine Tan-Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/32/1546/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/32/1546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22077833\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) coexist in up to 80 percent of women with pelvic floor dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While these conditions are often concurrent, one may be mild or asymptomatic. Women without symptoms of SUI who undergo surgery for prolapse are at risk for postoperative urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/3\">",
"     3",
"    </a>",
"    ]. SUI may also worsen after prolapse repair.",
"   </p>",
"   <p>",
"    Deciding whether to perform a combined surgical procedure to treat both prolapse and SUI or a single procedure that addresses only one condition requires balancing the risk of incomplete treatment with the risk of exposing the patient to unnecessary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/4\">",
"     4",
"    </a>",
"    ]. This decision must be based on the best approach to address the patient's goals, rather than simply on anatomic correction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Challenges in surgical decision-making in this clinical context include appropriate assessment of results of preoperative evaluation, some of which may be ambiguous (eg, prolapse noted on examination in a patient with no prolapse-related symptoms or a patient with advance prolapse with no leakage on prolapse reduction testing).",
"   </p>",
"   <p>",
"    Combined surgical treatment for POP and SUI will be reviewed here. Other approaches to surgical and medical treatment of these conditions and other types of urinary incontinence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI) &mdash; Leakage of urine with increased intraabdominal pressure (eg, cough, laughter). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Types of urinary incontinence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Occult SUI &mdash; SUI that is not symptomatic, but becomes apparent only during clinical or urodynamic urinary function testing when the prolapse is reduced (ie, stress testing with reduction of prolapsed structures). Occult stress incontinence is also referred to as latent, hidden, iatrogenic, or potential.",
"      <br/>",
"      <br/>",
"      The definition of occult SUI is inconsistent in the medical literature. While some authors use the term to describe only incontinence which has been demonstrated on urinary function testing (as in this topic review), others use the term occult incontinence to signify that there is a possibility that SUI will occur after prolapse repair.",
"     </li>",
"     <li>",
"      De novo urinary incontinence &mdash; Urinary incontinence that is newly symptomatic, as an example, incontinence symptoms that develop after surgery in a previously continent patient. The type of new incontinence should be specified (eg, stress, urge). As an example, a patient with urge incontinence and no SUI before surgery may have persistent urge incontinence and de novo stress incontinence after surgery.",
"     </li>",
"     <li>",
"      Prolapse reduction testing &mdash; Elevation of prolapsed structures to approximate normal pelvic support during pelvic examination or clinical or urodynamic urinary function testing. This is performed in combination with a urinary stress test (cough test) to attempt to detect occult SUI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) may present alone or concurrently in a variety of combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptomatic prolapse and incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of both POP and SUI may be part of the presenting complaint. On the other hand, POP symptoms may be nonspecific (pelvic pressure or discomfort) and some women only recognize these as related to POP after evaluation by a clinician. The symptoms of prolapse and incontinence may be equally bothersome or one condition may predominate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\", section on 'Types of urinary incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prolapse with no symptoms of incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced POP (pelvic organ prolapse quantitation system [POP-Q] stage II to IV) commonly coexists with SUI, however, for many women the SUI may become apparent only when the prolapse has been corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/1\">",
"     1",
"    </a>",
"    ]. This phenomenon is known as occult SUI. Testing for occult SUI is discussed below (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Detecting occult incontinence'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Anatomically, this occurs because in women with significant anterior or apical prolapse (usually prolapse past the vaginal introitus), the bladder neck is displaced posteriorly and the urethra is kinked, resulting in urethral obstruction. The obstruction then becomes the mechanism of continence (",
"    <a class=\"graphic graphic_figure graphicRef85778 \" href=\"UTD.htm?42/58/43939\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the prolapsed structures are elevated (approximating normal anatomy) during prolapse reduction testing in women with urethral obstruction due to advanced POP, the urethra is unblocked and SUI often becomes evident when a urinary stress test is performed. On the other hand, women with stage I POP are unlikely to have urethral obstruction and resultant occult SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Detecting occult incontinence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occult SUI is diagnosed using preoperative prolapse reduction testing in 31 to 80 percent of women with symptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced POP who are planning surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12-25\">",
"     12-25",
"    </a>",
"    ]. Accordingly, when women with occult SUI undergo prolapse repair without a concomitant continence procedure, the rate of postoperative de novo SUI ranges in studies from 13 to 72 percent (mean 51 percent) (",
"    <a class=\"graphic graphic_algorithm graphicRef66014 \" href=\"UTD.htm?38/3/38964\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, women who have negative preoperative testing for occult SUI and undergo prolapse repair without a continence procedure may still develop SUI after surgery, but at a lower rate than women who test positive for occult SUI with preoperative prolapse reduction testing. The rate of postoperative incontinence in women with negative preoperative occult stress testing ranges in studies from 0 to 42 percent (mean 26 percent) (",
"    <a class=\"graphic graphic_algorithm graphicRef66014 \" href=\"UTD.htm?38/3/38964\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/13-15,17,26-30\">",
"     13-15,17,26-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incontinence with no symptoms of prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with SUI will often have POP of varying degrees. Treatment is indicated only for symptomatic POP. Approximately 40 percent of women are found to have stage II or greater prolapse at annual gynecologic examination; however, symptoms related to prolapse often do not correspond with anatomical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524755#H21524755\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are considering pelvic reconstructive surgery for pelvic organ prolapse (POP) or stress urinary incontinence (SUI) should have a comprehensive evaluation to guide surgical planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical history and symptoms related to POP and SUI (a voiding diary may be useful (",
"      <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"       figure 2",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Pelvic examination with objective quantification of prolapse",
"     </li>",
"     <li>",
"      Clinical or urodynamic urinary stress testing with and without reduction of prolapse",
"     </li>",
"     <li>",
"      Assessment of patient goals and quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic and preoperative evaluation of women with POP or SUI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=see_link\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Detecting occult incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult SUI can be detected by medical history and clinical or urodynamic testing with reduction of prolapsed structures.",
"   </p>",
"   <p>",
"    Clues in the history that suggest occult SUI include (1) incontinence that improved or resolved as prolapse worsened; (2) the need to manually replace the prolapsed structures into the vagina to void; or (3) worsening or development of SUI with use of a pessary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On clinical bladder function testing or urodynamic testing, women with POP should be evaluated with and without reduction of prolapse. The purpose is to simulate the patient's vaginal architecture after surgical repair. Reducing the prolapse will often reduce a previously elevated postvoid residual and unmask SUI.",
"   </p>",
"   <p>",
"    Prolapse reduction should be performed while the patient is standing. While elevating the prolapsed structures, it is important to avoid obstructing the urethra, which would mask incontinence. One should also avoid placing the anterior vaginal wall under excessive tension, which could distort the pelvic anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common methods of prolapse reduction use the following to elevate the structures: examiner's fingers, large cotton swab, single speculum blade, ring forceps, or pessary. While there are few data comparing these methods, using a pessary may be less effective at detecting SUI than other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/15,31\">",
"     15,31",
"    </a>",
"    ]. This is likely because incontinence pessaries increase the maximum urethral closure pressure and functional urethral length and, thus, are often used to treat SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/32\">",
"     32",
"    </a>",
"    ]. Some data suggest that the bladder should be filled to at least 300 mL; in one study, occult SUI identified with use of a bladder volume of 300 mL was more likely than 100 mL to be associated with postoperative SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study to evaluate prolapse reduction testing, data regarding prolapse reduction using five methods (manual, swab, speculum, forceps, pessary) were collected in women with advanced prolapse, but without symptoms of SUI (n = 322) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/15\">",
"     15",
"    </a>",
"    ]. The sensitivity for detection of occult SUI was similar among most reduction testing methods (17 to 39 percent), with the exception of the pessary, which was less sensitive (5 percent). In our practice, we use one or two large cotton swabs because it is well tolerated by patients and the swabs are long enough to approximate a surgical suspension of the vaginal apex.",
"   </p>",
"   <p>",
"    Prolapse reduction testing may be performed as part of office testing of SUI or during urodynamic evaluation. Both approaches appear to have a similar predictive value for the development of postoperative SUI. This is based upon data from two prospective studies of women who underwent preoperative prolapse reduction testing and were treated with a prolapse repair procedure, but no continence procedure. Urodynamic evaluation was used in one study, and the rate of postoperative de novo SUI was 58 percent for women who tested positive for preoperative occult SUI and 38 percent for those who tested negative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/15\">",
"     15",
"    </a>",
"    ]. In the other study, office testing was used, and the rate of de novo SUI was 72 percent for women who tested positive and 38 percent for women who tested negative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies define occult SUI as leakage with prolapse reduction during office testing or urodynamic evaluation, but some reports used maximum urethral closure pressures or pressure transmission ratios of &lt;0.9 or 1.0 during urodynamic evaluation to indicate a positive test. During urodynamic testing, prolapse reduction decreases maximal urethral closure pressure, but does not alter any other filling or pressure flow parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=see_link\">",
"     \"Urodynamic evaluation of women with incontinence\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The predictive value of prolapse reduction testing is limited. The results of numerous studies evaluating the risk of postoperative SUI in women undergoing prolapse surgery with various clinical scenarios are summarized in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef66014 \" href=\"UTD.htm?38/3/38964\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/13-15,17,19,20,26-28,34-45\">",
"     13-15,17,19,20,26-28,34-45",
"    </a>",
"    ]. Overall, in women without symptoms of SUI who have",
"    <strong>",
"     positive",
"    </strong>",
"    preoperative prolapse reduction testing, the rate of postoperative SUI is 51 percent without an incontinence procedure and 16 percent with an incontinence procedure. In asymptomatic women who have",
"    <strong>",
"     negative",
"    </strong>",
"    prolapse reduction testing, the rate of postoperative SUI is 26 percent without an incontinence procedure and 17 percent with an incontinence procedure.",
"   </p>",
"   <p>",
"    In the absence of more effective methods to detect occult SUI, however, reduction testing should be performed in all women planning vaginal pelvic floor reconstructive surgery. Further study is needed to identify other methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Informed consent and patient goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women planning surgical correction of pelvic floor reconstructive surgery should be counseled about the potential for incomplete resolution of symptoms, or new symptoms of SUI, urinary retention or urge incontinence.",
"   </p>",
"   <p>",
"    Discussing patient goals and setting expectations can also help both the patient and surgeon measure surgical success. Achievement of patient goals, including symptom resolution, or improvement in lifestyle, activity, or sexual function, correlate with postoperative satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H7157274#H7157274\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Establishing patient goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHOOSING AN ABDOMINAL OR VAGINAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with both stress urinary incontinence (SUI) and pelvic organ prolapse (POP), the surgical route (vaginal or abdominal, including laparoscopic or robotic procedures) is chosen that is most appropriate for the anatomic site of prolapse (ie, anterior, apical, posterior) with the goal of avoiding incisions in two sites. An abdominal approach typically includes a sacrocolpopexy and Burch colposuspension, while a vaginal approach may include a uterosacral ligament fixation (or other transvaginal procedure) and suburethral sling (typically a midurethral sling).",
"   </p>",
"   <p>",
"    Additional factors to consider in choosing a route are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical history &ndash; comorbidities, prior surgeries",
"     </li>",
"     <li>",
"      Procedure efficacy &ndash; this depends upon procedure and surgeon's experience [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patient preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most combined procedures are performed vaginally for several reasons. Midurethral sling placement, a vaginal approach, is the preferred procedure for most women with SUI. Also, repair of anterior and posterior prolapse are usually performed vaginally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exception to this is apical prolapse, which is commonly repaired using an abdominal (open or laparoscopic) sacrocolpopexy. Apical prolapse can also be repaired via a vaginal route, with sacrospinous or uterosacral ligament suspension. The choice of route for women with apical prolapse then depends upon the best combination of procedures: (1) midurethral sling and sacrospinous or uterosacral ligament suspension or (2) Burch colposuspension and abdominal sacrocolpopexy. Evidence from randomized trials has demonstrated that abdominal repairs are more durable, while vaginal repairs have fewer complications, including foreign body complications. Comparison of surgical outcomes for specific procedures is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=see_link&amp;anchor=H21188326#H21188326\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Vaginal versus abdominal approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, some surgeons combine sacral colpopexy with a midurethral sling, particularly when a laparoscopic or robotic approach is used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H20#H20\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Apical prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16125469\">",
"    <span class=\"h1\">",
"     SELECTION OF PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of symptoms and findings on preoperative evaluation guide the choice of procedure for treatment of pelvic organ prolapse (POP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stress urinary incontinence (SUI). Choosing a procedure that addresses either POP or SUI or a combined procedure for different clinical scenarios is discussed here.",
"   </p>",
"   <p>",
"    The choice of a primary procedure for treatment of SUI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16125477\">",
"    <span class=\"h2\">",
"     Symptomatic POP and SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with symptoms of both POP and SUI, we recommend a concomitant prolapse repair and continence procedure rather than POP repair alone. Data from prospective comparative studies of women with both symptomatic POP and SUI show a significantly lower rate of postoperative SUI in women who undergo both POP repair and a continence procedure compared with those who undergo POP repair alone (0 to 40 versus 36 to 71 percent) (",
"    <a class=\"graphic graphic_algorithm graphicRef66014 \" href=\"UTD.htm?38/3/38964\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/34,41,43-45\">",
"     34,41,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no single procedure that adequately treats both POP and SUI. Historically, the only example of a POP repair procedure that was performed with the intention of treating SUI was anterior colporrhaphy alone or with a Kelly-Kennedy plication. This approach has been found to be less effective for treatment of SUI than a Burch colposuspension based upon randomized trial data. Likewise, available continence procedures (suburethral slings, Burch colposuspension) are not effective for treating symptoms associated with POP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link&amp;anchor=H9#H9\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\", section on 'Procedures no longer recommended'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     POP with no symptoms of SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with symptomatic POP, but no SUI symptoms is controversial. Continent women with stage I POP who are planning prolapse repair are unlikely to have urethral obstruction and resultant occult SUI, and thus are unlikely to benefit from a concomitant continence procedure. However, for women with advanced prolapse, there is a high likelihood that they will develop SUI postoperatively.",
"   </p>",
"   <p>",
"    There are three possible approaches for addressing potential SUI at the time of POP treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Universal",
"      </strong>",
"      &ndash; A continence procedure is performed at the time of POP surgery, regardless of preoperative prolapse reduction and urinary stress testing. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Selective",
"      </strong>",
"      &ndash; Preoperative prolapse reduction and urinary stress testing is performed. If occult SUI is detected, a continence procedure is performed at the time of POP repair. If occult SUI is not detected, POP repair alone is performed.",
"     </li>",
"     <li>",
"      <strong>",
"       Staged",
"      </strong>",
"      &ndash; POP repair is performed without a concomitant SUI procedure, regardless of preoperative prolapse reduction and urinary stress testing. A subsequent continence procedure is performed if SUI symptoms develop and the patient desires surgical treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these approaches is best supported by data from two large randomized trials, one for an abdominal surgical approach and one for a vaginal approach.",
"   </p>",
"   <p>",
"    Regarding an abdominal approach, the Colpopexy and Urinary Reduction Efforts (CARE) trial supports the universal approach. In the CARE trial, women without SUI symptoms with stage II to IV prolapse were assigned to undergo open sacrocolpopexy with or without Burch colposuspension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/3,47-49\">",
"     3,47-49",
"    </a>",
"    ]. Postoperatively, women who developed de novo SUI were identified using questionnaires, medical visits seeking treatment for SUI, and positive findings on stress testing. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with advanced POP who were continent before surgery, prophylactic Burch colposuspension at the time of open abdominal sacrocolpopexy reduced postoperative SUI. The rate of SUI was statistically significantly lower in the Burch versus no Burch group at 3-month (24 and 44 percent) and 24-month follow-up (32 and 45 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/3,49\">",
"       3,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of postoperative SUI was higher in women with occult SUI on preoperative urodynamic prolapse reduction and urinary stress testing, but was also present at clinically significant rates in women with no occult SUI. In a subset analysis divided into groups by preoperative testing results, the rates of de novo postoperative SUI at three months were [",
"      <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/13\">",
"       13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Occult SUI: 37 percent in the Burch group; 60 percent in the no Burch group",
"     </li>",
"     <li>",
"      No occult SUI: 20 percent in the Burch group; 39 percent in the no Burch group",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of the Burch did not increase the frequency of urinary retention, urge incontinence, urinary urgency, urinary tract infection (UTI), or other perioperative complications. Although colposuspension is not a treatment for urge incontinence, the rate of urgency symptoms was lower in the Burch group at 24-month follow-up (32 versus 45 percent), but the difference was not statistically significant.",
"     </li>",
"     <li>",
"      The rate of bothersome SUI symptoms was significantly lower in the Burch group at 24-month follow-up (12 versus 25 percent), and the rate of subsequent treatment for SUI was lower in the Burch group, but this did not reach statistical significance (13 versus 20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regarding a vaginal approach, the Outcomes Following Vaginal Prolapse Repair and Midurethral Sling (OPUS) trial found a similar degree of benefit in preventing de novo SUI as in the CARE trial, but the risk of complications was higher in women who underwent a continence procedure. In the OPUS trial, women without SUI symptoms with stage II to IV prolapse were assigned to undergo transvaginal prolapse repair (apical suspension, anterior repair, colpocleisis) with either a retropubic midurethral sling (TVT&trade;) or sham bilateral suprapubic incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperatively, women who developed de novo SUI were identified using questionnaires, medical visits seeking treatment for SUI, and positive findings on stress testing. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with advanced POP who were continent before surgery, a prophylactic retropubic midurethral sling at the time of vaginal prolapse repair reduced the rate of postoperative urinary incontinence. The rate of incontinence (stress, urge, or mixed) or treatment for incontinence was significantly lower in the sling versus sham group at three-month follow-up (24 versus 49 percent). The rate of urinary incontinence continued to be significantly lower in the sling group at 12-month follow-up (27 and 43 percent).",
"     </li>",
"     <li>",
"      The rate of postoperative urinary incontinence was higher in women with occult SUI on preoperative office&ndash;based prolapse reduction and urinary stress testing, but was also present at clinically significant rates in women with no occult SUI. In a subset analysis divided into groups by preoperative testing results, the rates of urinary incontinence at three months were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Occult SUI: 30 percent in the sling group; 72 percent in the sham group.",
"     </li>",
"     <li>",
"      No occult SUI: 21 percent in the sling group; 38 percent in the sham group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of serious adverse events did not differ significantly between the sling and sham groups (17 versus 12 percent). However, women in the sling group had significantly higher rates of bladder perforation (11 versus 0 women; 7 versus 0 percent); incomplete bladder emptying (at six weeks postoperatively) (6 versus 0 women; 4 versus 0 percent); and urinary tract infection (31 versus 18 percent). All bladder perforation was managed intraoperatively with removal and replacement of the trocar.",
"     </li>",
"     <li>",
"      The rate of subsequent treatment for incontinence was lower in the sling group, but some women in the sling group required subsequent surgery for voiding dysfunction. At 12-month follow-up:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sling group: 12 women were treated for incontinence (7.3 percent), including 1 who had surgery (0.6 percent), and 4 women had surgery for voiding dysfunction (2.4 percent)",
"     </li>",
"     <li>",
"      Sham group: 19 women were treated (11.0 percent), including 8 who underwent surgery (4.7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the data from these two trials, the approach to continent women planning POP repair depends upon the surgical approach and whether they were found to have occult SUI on preoperative prolapse reduction and urinary stress testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16125530\">",
"    <span class=\"h3\">",
"     Abdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For continent women with stage II or greater POP who are undergoing abdominal sacrocolpopexy without concurrent transvaginal repairs (eg, colporrhaphy), a",
"    <strong>",
"     universal approach",
"    </strong>",
"    is optimal. For these women, regardless of the results of preoperative testing for occult SUI, we recommend a concomitant Burch colposuspension rather than sacrocolpopexy alone. &nbsp;",
"   </p>",
"   <p>",
"    A concomitant procedure avoids the morbidity and recovery time required for two separate abdominal surgeries. The evidence to support this comes from the CARE study, as discussed above, in which benefit was observed in those with either positive or negative prolapse reduction testing and no increase in adverse events was observed in women who underwent a Burch procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/3,49\">",
"     3,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H501610\">",
"    <span class=\"h3\">",
"     Vaginal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to management is less clear for women with POP but no symptoms of SUI who are undergoing vaginal surgery. A shared decision making process with the patient is required. Patient counseling should include the potential benefits of the prophylactic continence surgery (based upon the results of preoperative prolapse reduction and urinary stress testing), potential complications, and patient goals and preferences. &nbsp;",
"   </p>",
"   <p>",
"    The best evidence to guide clinical decision-making for these women is from the OPUS trial, as discussed above, which demonstrated that these women receive a degree of benefit from prophylactic continence surgery that is similar to women who undergo abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the addition of a prophylactic midurethral sling increases the risk of complications. Complications such as bladder perforation or UTI typically do not add significantly to postoperative morbidity, and resolve either with intraoperative treatment or short-term use of a bladder catheter or antibiotic therapy. However, some women will have persistent voiding dysfunction following midurethral sling surgery, requiring prolonged catheterization and potentially a subsequent surgical procedure. The rate of urethrolysis in the OPUS trial (2.4 percent) was consistent with the rate of post-sling persistent voiding dysfunction reported in other studies (0.6 to 2.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. This is an important consideration, since one of the principal benefits of prophylactic continence surgery is avoiding the need for a subsequent surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H4701484#H4701484\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Voiding dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available evidence and clinical considerations, for women undergoing vaginal surgery we use a",
"    <strong>",
"     selective approach",
"    </strong>",
"    , but some women with negative preoperative testing for occult SUI may reasonably choose a",
"    <strong>",
"     staged approach",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Based upon the OPUS trial data, using a universal approach, the number needed to treat in order to prevent one case of urinary incontinence at 12 months was 6.3, although there was modest evidence to suggest that patients with a positive prolapse reduction stress test before surgery received more benefit than those with a negative test.",
"   </p>",
"   <p>",
"    Many experts consider women with positive testing for occult SUI to be similar to women who present with SUI symptoms, and advise a combined procedure for prolapse and SUI. Women with a positive preoperative prolapse reduction stress test are at the highest risk of postoperative SUI. In the OPUS trial, there was modest evidence to suggest that patients with a positive prolapse reduction stress test before surgery received more benefit than those with a negative test. The overall positive predictive value of the preoperative prolapse reduction stress for postoperative SUI based upon multiple studies is 51 percent (",
"    <a class=\"graphic graphic_algorithm graphicRef66014 \" href=\"UTD.htm?38/3/38964\">",
"     algorithm 1",
"    </a>",
"    ) and it was 72 percent in the OPUS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12-15,34,52,53\">",
"     12-15,34,52,53",
"    </a>",
"    ]. Using a selective approach and performing continence surgery only in women with a positive prolapse reduction stress test, the number needed to treat in order to prevent one case of urinary incontinence at three months was 2.4. &nbsp;",
"   </p>",
"   <p>",
"    For women with stage II or greater POP and",
"    <strong>",
"     positive",
"    </strong>",
"    preoperative testing for occult SUI, we recommend a combined procedure for prolapse and SUI rather than prolapse repair alone.",
"   </p>",
"   <p>",
"    On the other hand, women with negative preoperative testing for occult SUI should be counseled about the available options and the risks of urinary incontinence, perioperative complications, and voiding dysfunction. Management of these women depends upon their values and preferences.",
"   </p>",
"   <p>",
"    Concomitant continence surgery in the OPUS trial in this patient population resulted in an absolute risk reduction for postoperative urinary incontinence of 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"     12",
"    </a>",
"    ]. This rate was clinically significant, but must be considered in relation to the risk of sling-related complications and associated morbidity.",
"   </p>",
"   <p>",
"    If a staged approach is used, a patient with stage II or greater POP without symptoms of SUI would only undergo surgery for POP with no concomitant continence procedure. The staged procedure typically takes place within one year of the original prolapse repair and it is performed only if the patient develops symptoms of bothersome SUI requiring correction. The advantage of this approach is that unnecessary procedures would be avoided. The OPUS trial demonstrated that, for women who underwent only vaginal POP repair, 49 percent developed SUI, but only 5 percent had a sling procedure in the first year. Compared with a universal approach, the staged approach resulted in a 95 percent reduction in the number of slings placed.",
"   </p>",
"   <p>",
"    Given the available data and clinical considerations, for women with stage II or greater POP who are undergoing",
"    <strong>",
"     vaginal surgery",
"    </strong>",
"    and who have",
"    <strong>",
"     NEGATIVE",
"    </strong>",
"    preoperative testing for occult SUI, we suggest prolapse repair alone rather than a combined procedure for prolapse and SUI. Concomitant POP repair and continence surgery is a reasonable option for women who place a high priority on avoiding postoperative urinary incontinence and are willing to accept an increased risk of perioperative complications and voiding dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H502447\">",
"    <span class=\"h4\">",
"     Concomitant versus staged procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experts have questioned whether the SUI cure rate is impacted depending upon whether the continence surgery is performed alone or concomitant with a POP repair procedure, but there appears to be no difference based upon available data.",
"   </p>",
"   <p>",
"    This issue was evaluated in a multicenter randomized trial of women with POP and SUI who were assigned to have a tension-free vaginal tape (TVT) either concomitant with prolapse repair or a staged procedure (prolapse repair followed by TVT three months later) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/45\">",
"     45",
"    </a>",
"    ]. In an intent-to-treat analysis, at one-year follow-up, there was no significant difference between the concomitant compared with staged groups in SUI cure rate (95 versus 89 percent) or total operative complications (18 versus 13 percent). Of note, in the staged group, TVT was ultimately performed only in women who had confirmed SUI at three months after prolapse repair (56 percent). Among the women in the staged group who did not undergo TVT, one-year outcomes were as follows: 27 percent were still continent and 15 percent had some SUI, but declined TVT.",
"   </p>",
"   <p>",
"    In observational data from another trial, in which women were randomized to undergo either a retropubic or transobturator midurethral sling, those who did versus did not have concomitant surgery had significantly higher objective cure rates (88 versus 79 percent), but not subjective cure rates (62 versus 58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, observational comparative studies have found no significant difference in the SUI cure rate for women who underwent midurethral sling placement alone compared to sling placement combined with vaginal surgery (hysterectomy or prolapse repair) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. In a prospective cohort study, women who underwent prolapse repair concomitantly with midurethral sling placement, compared with those who planned a staged procedure, had no significant differences in SUI symptoms (22 versus 21 percent), change in severity of SUI, or satisfaction (8.8 verus 9.2 on a 10 point scale) at one-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/58\">",
"     58",
"    </a>",
"    ]. Of note, only 33 percent of the women in the planned staged group underwent sling placement within the study period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     SUI with asymptomatic POP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse, particularly stages I or II, is often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Thus, women who present with symptoms of SUI only, but have POP on examination, present a treatment dilemma. The issue is whether repair of asymptomatic prolapse provides a woman with a long-term benefit (eg, prevention of subsequent symptoms or surgery) or if it only increases the risk of perioperative complications.",
"   </p>",
"   <p>",
"    An important question is whether prolapse in these women will worsen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    become symptomatic with age or after menopause. Surprisingly, the natural history of prolapse does not follow a progressive course in all women. Data suggest that the course is progressive until menopause, after which the degree of prolapse may follow a course of alternating progression and regression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with ongoing risk factors for POP are likely to have progression. These include increasing parity, hysterectomy, obesity, and chronic constipation. For obese women, weight loss does not appear to result in regression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=see_link&amp;anchor=H21524727#H21524727\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although natural regression of prolapse may occur, combined surgical treatment for SUI and POP appears to reduce the risk of subsequent surgery. This was illustrated in a retrospective study of insurance claims by over 1000 women who underwent a sling procedure for SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/46\">",
"     46",
"    </a>",
"    ]. Compared to women who did not undergo concomitant prolapse repair, women who had a concomitant repair were significantly less likely to have subsequent surgery for SUI or prolapse within one year of the initial surgery (SUI: 5 versus 10 percent; POP: 14 versus 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/46\">",
"     46",
"    </a>",
"    ]. However, women who had a combined SUI and POP repair were also significantly more likely to have postoperative urethral obstruction (9 versus 6 percent). This study was limited by the lack of data on the stage of prolapse and whether symptoms were present, thus making it uncertain whether the results apply to asymptomatic women.",
"   </p>",
"   <p>",
"    Additional surgical procedures increase operative time and may increase the risk of perioperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/3,63\">",
"     3,63",
"    </a>",
"    ]. In the study described above, concurrent surgery for SUI and POP was associated with an increase in postoperative urethral obstruction. However, it is controversial whether combined procedures lead to an increase in obstructive urinary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/46,63-67\">",
"     46,63-67",
"    </a>",
"    ]. There are no high quality studies of combined surgery for women with SUI and mild or asymptomatic prolapse.",
"   </p>",
"   <p>",
"    Given the available data and clinical considerations, for women with stage I asymptomatic prolapse, we suggest",
"    <strong>",
"     NOT",
"    </strong>",
"    performing prolapse repair at the time of continence surgery. Since prolapse has not been proven to be progressive and stage I prolapse is almost never symptomatic, repair in these women appears to be unnecessary. Treatment of women with stage II or greater prolapse who are asymptomatic must be individualized based upon a discussion with the patient about her treatment goals and the risk of subsequent surgery. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Informed consent and patient goals'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Women at high surgical risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the degree of surgical risk, women with stress urinary incontinence (SUI) and pelvic organ prolapse (POP) can be treated using conservative measures (eg, pessary, pelvic floor exercises), however, surgery may be an option for some. Colpocleisis (surgical obliteration of the vaginal lumen) is the procedure of choice in women at high surgical risk who are not planning further sexual intercourse and desire surgical treatment. This procedure involves minimal surgical risk and can be combined safely and effectively with a sling procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/32/1546/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=see_link\">",
"     \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Women planning future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women planning future pregnancy should not undergo pelvic floor reconstructive surgery, since pelvic support may be disrupted during pregnancy and delivery and further surgery may be necessary after pregnancy. Conservative measures are appropriate treatment for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) coexist in up to 80 percent of women with pelvic floor symptoms. This correlation between these conditions is due to their common pathophysiology. (See",
"      <a class=\"local\" href=\"#H22077833\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A woman may find symptoms of prolapse and incontinence equally bothersome or one condition may predominate or be asymptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 80 percent of women with advanced POP have occult SUI caused by urethral obstruction. These women are at risk of developing SUI after prolapse repair. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prolapse with no symptoms of incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women who are considering pelvic reconstructive surgery should have a comprehensive evaluation for both prolapse and urinary incontinence before treatment is planned, including: assessment of urinary symptoms, pelvic examination with objective quantification of prolapse, clinical or urodynamic urinary stress testing with reduction of prolapse, and discussion of patient goals and quality of life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative prolapse reduction testing has a positive predictive value above 50 percent for postoperative SUI.",
"     </li>",
"     <li>",
"      For women with symptoms of both POP and SUI, we recommend a concomitant prolapse repair and continence procedure rather than POP repair alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16125477\">",
"       'Symptomatic POP and SUI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with symptomatic POP and no SUI symptoms (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Prolapse with no symptoms of incontinence'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continent women with stage I POP who are planning prolapse repair are unlikely to have urethral obstruction and resultant occult SUI, and thus are unlikely to benefit from a concomitant continence procedure.",
"     </li>",
"     <li>",
"      For women with stage II or greater POP who are undergoing",
"      <strong>",
"       abdominal sacrocolpopexy",
"      </strong>",
"      without concurrent vaginal repairs, regardless of the results of preoperative testing for occult SUI, we recommend a concomitant Burch colposuspension rather than sacrocolpopexy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16125530\">",
"       'Abdominal approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage II or greater POP who are undergoing",
"      <strong>",
"       vaginal surgery",
"      </strong>",
"      and who have",
"      <strong>",
"       POSITIVE",
"      </strong>",
"      preoperative testing for occult SUI, we recommend a concomitant POP repair and continence procedure rather than prolapse repair alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H501610\">",
"       'Vaginal approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage II or greater POP who are undergoing",
"      <strong>",
"       vaginal surgery",
"      </strong>",
"      and who have",
"      <strong>",
"       NEGATIVE",
"      </strong>",
"      preoperative testing for occult SUI, we suggest prolapse repair alone rather than a combined procedure for prolapse and SUI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Concomitant POP repair and continence surgery is a reasonable option for women who place a high priority on avoiding postoperative urinary incontinence and are willing to accept an increased risk of perioperative complications and voiding dysfunction. (See",
"      <a class=\"local\" href=\"#H501610\">",
"       'Vaginal approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with SUI and asymptomatic prolapse (see",
"      <a class=\"local\" href=\"#H16\">",
"       'SUI with asymptomatic POP'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with stage I prolapse, we suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      performing prolapse repair at the time of continence surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Treatment of women with stage II or greater prolapse must be individualized according to patient treatment goals and the risk of subsequent surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choice of an abdominal or vaginal approach is made based on the following factors: anatomic location of the prolapse, medical history, procedure efficacy, patient preference, and surgeon's experience. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Choosing an abdominal or vaginal approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/1\">",
"      Bai SW, Jeon MJ, Kim JY, et al. Relationship between stress urinary incontinence and pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/2\">",
"      Maher CM, Feiner B, Baessler K, Glazener CM. Surgical management of pelvic organ prolapse in women: the updated summary version Cochrane review. Int Urogynecol J 2011; 22:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/3\">",
"      Brubaker L, Cundiff GW, Fine P, et al. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. N Engl J Med 2006; 354:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/4\">",
"      Winters JC. A critical appraisal of preventive slings and prolapse surgery--what's a urologist to do? J Urol 2008; 180:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/5\">",
"      Elkadry EA, Kenton KS, FitzGerald MP, et al. Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 2003; 189:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/6\">",
"      Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/7\">",
"      Mueller ER, Kenton K, Mahajan S, et al. Urodynamic prolapse reduction alters urethral pressure but not filling or pressure flow parameters. J Urol 2007; 177:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/8\">",
"      Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001; 185:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/9\">",
"      Gutman RE, Ford DE, Quiroz LH, et al. Is there a pelvic organ prolapse threshold that predicts pelvic floor symptoms? Am J Obstet Gynecol 2008; 199:683.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/10\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     Mouritsen, L, Larsen, JP. Symptoms, bother and POPQ in women referred with pelvic organ.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/12\">",
"      Wei JT, Nygaard I, Richter HE, et al. A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med 2012; 366:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/13\">",
"      Liang CC, Chang YL, Chang SD, et al. Pessary test to predict postoperative urinary incontinence in women undergoing hysterectomy for prolapse. Obstet Gynecol 2004; 104:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/14\">",
"      Reena C, Kekre AN, Kekre N. Occult stress incontinence in women with pelvic organ prolapse. Int J Gynaecol Obstet 2007; 97:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/15\">",
"      Visco AG, Brubaker L, Nygaard I, et al. The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the Colpopexy and Urinary Reduction Efforts (CARE) randomized surgical trial. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/16\">",
"      Bump RC, Fantl JA, Hurt WG. The mechanism of urinary continence in women with severe uterovaginal prolapse: results of barrier studies. Obstet Gynecol 1988; 72:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/17\">",
"      Chaikin DC, Groutz A, Blaivas JG. Predicting the need for anti-incontinence surgery in continent women undergoing repair of severe urogenital prolapse. J Urol 2000; 163:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/18\">",
"      Gallentine ML, Cespedes RD. Occult stress urinary incontinence and the effect of vaginal vault prolapse on abdominal leak point pressures. Urology 2001; 57:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/19\">",
"      Gordon D, Gold RS, Pauzner D, et al. Combined genitourinary prolapse repair and prophylactic tension-free vaginal tape in women with severe prolapse and occult stress urinary incontinence: preliminary results. Urology 2001; 58:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/20\">",
"      Groutz A, Gold R, Pauzner D, et al. Tension-free vaginal tape (TVT) for the treatment of occult stress urinary incontinence in women undergoing prolapse repair: a prospective study of 100 consecutive cases. Neurourol Urodyn 2004; 23:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/21\">",
"      Richardson DA, Bent AE, Ostergard DR. The effect of uterovaginal prolapse on urethrovesical pressure dynamics. Am J Obstet Gynecol 1983; 146:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/22\">",
"      Rosenzweig BA, Pushkin S, Blumenfeld D, Bhatia NN. Prevalence of abnormal urodynamic test results in continent women with severe genitourinary prolapse. Obstet Gynecol 1992; 79:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/23\">",
"      Sinha D, Arunkalaivanan AS. Prevalence of occult stress incontinence in continent women with severe genital prolapse. J Obstet Gynaecol 2007; 27:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/24\">",
"      Stanton SL, Hilton P, Norton C, Cardozo L. Clinical and urodynamic effects of anterior colporrhaphy and vaginal hysterectomy for prolapse with and without incontinence. Br J Obstet Gynaecol 1982; 89:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/25\">",
"      Groutz A, Levin I, Gold R, et al. \"Inside-out\" transobturator tension-free vaginal tape for management of occult stress urinary incontinence in women undergoing pelvic organ prolapse repair. Urology 2010; 76:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/26\">",
"      Bergman A, Koonings PP, Ballard CA. Predicting postoperative urinary incontinence development in women undergoing operation for genitourinary prolapse. Am J Obstet Gynecol 1988; 158:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/27\">",
"      Colombo M, Maggioni A, Zanetta G, et al. Prevention of postoperative urinary stress incontinence after surgery for genitourinary prolapse. Obstet Gynecol 1996; 87:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/28\">",
"      Klutke JJ, Ramos S. Urodynamic outcome after surgery for severe prolapse and potential stress incontinence. Am J Obstet Gynecol 2000; 182:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/29\">",
"      Al-Mandeel H, Ross S, Robert M, Milne J. Incidence of stress urinary incontinence following vaginal repair of pelvic organ prolapse in objectively continent women. Neurourol Urodyn 2011; 30:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/30\">",
"      Kasturi S, Diaz SI, McDermott CD, et al. De novo stress urinary incontinence after negative prolapse reduction stress testing for total vaginal mesh procedures: incidence and risk factors. Am J Obstet Gynecol 2011; 205:487.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/31\">",
"      Veronikis DK, Nichols DH, Wakamatsu MM. The incidence of low-pressure urethra as a function of prolapse-reducing technique in patients with massive pelvic organ prolapse (maximum descent at all vaginal sites). Am J Obstet Gynecol 1997; 177:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/32\">",
"      Bhatia NN, Bergman A, Gunning JE. Urodynamic effects of a vaginal pessary in women with stress urinary incontinence. Am J Obstet Gynecol 1983; 147:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/33\">",
"      Svenningsen R, Borstad E, Spydslaug AE, et al. Occult incontinence as predictor for postoperative stress urinary incontinence following pelvic organ prolapse surgery. Int Urogynecol J 2012; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/34\">",
"      de Tayrac R, Gervaise A, Chauveaud-Lambling A, Fernandez H. Combined genital prolapse repair reinforced with a polypropylene mesh and tension-free vaginal tape in women with genital prolapse and stress urinary incontinence: a retrospective case-control study with short-term follow-up. Acta Obstet Gynecol Scand 2004; 83:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/35\">",
"      Barnes NM, Dmochowski RR, Park R, Nitti VW. Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology 2002; 59:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/36\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/37\">",
"      Subak LL, Waetjen LE, van den Eeden S, et al. Cost of pelvic organ prolapse surgery in the United States. Obstet Gynecol 2001; 98:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/38\">",
"      Borstad E, Rud T. The risk of developing urinary stress-incontinence after vaginal repair in continent women. A clinical and urodynamic follow-up study. Acta Obstet Gynecol Scand 1989; 68:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/39\">",
"      Bump RC, Hurt WG, Theofrastous JP, et al. Randomized prospective comparison of needle colposuspension versus endopelvic fascia plication for potential stress incontinence prophylaxis in women undergoing vaginal reconstruction for stage III or IV pelvic organ prolapse. The Continence Program for Women Research Group. Am J Obstet Gynecol 1996; 175:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/40\">",
"      Colombo M, Maggioni A, Scalambrino S, et al. Surgery for genitourinary prolapse and stress incontinence: a randomized trial of posterior pubourethral ligament plication and Pereyra suspension. Am J Obstet Gynecol 1997; 176:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/41\">",
"      Colombo M, Vitobello D, Proietti F, Milani R. Randomised comparison of Burch colposuspension versus anterior colporrhaphy in women with stress urinary incontinence and anterior vaginal wall prolapse. BJOG 2000; 107:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/42\">",
"      Groutz A, Gordon D, Wolman I, et al. The use of prophylactic Stamey bladder neck suspension to prevent post-operative stress urinary incontinence in clinically continent women undergoing genitourinary prolapse repair. Neurourol Urodyn 2000; 19:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/43\">",
"      Partoll LM. Efficacy of tension-free vaginal tape with other pelvic reconstructive surgery. Am J Obstet Gynecol 2002; 186:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/44\">",
"      Wille S, Braun M, Heidenreich A, et al. Sacral colpopexy with concurrent Burch colposuspension in patients with vaginal vault prolapse. Urol Int 2006; 76:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/45\">",
"      Borstad E, Abdelnoor M, Staff AC, Kulseng-Hanssen S. Surgical strategies for women with pelvic organ prolapse and urinary stress incontinence. Int Urogynecol J 2010; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/46\">",
"      Anger JT, Litwin MS, Wang Q, et al. The effect of concomitant prolapse repair on sling outcomes. J Urol 2008; 180:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/47\">",
"      Brubaker L, Cundiff G, Fine P, et al. A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods. Control Clin Trials 2003; 24:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/48\">",
"      Burgio KL, Nygaard IE, Richter HE, et al. Bladder symptoms 1 year after abdominal sacrocolpopexy with and without Burch colposuspension in women without preoperative stress incontinence symptoms. Am J Obstet Gynecol 2007; 197:647.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/49\">",
"      Brubaker L, Nygaard I, Richter HE, et al. Two-year outcomes after sacrocolpopexy with and without burch to prevent stress urinary incontinence. Obstet Gynecol 2008; 112:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/50\">",
"      Rardin CR, Rosenblatt PL, Kohli N, et al. Release of tension-free vaginal tape for the treatment of refractory postoperative voiding dysfunction. Obstet Gynecol 2002; 100:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/51\">",
"      Laurikainen E, Kiilholma P. A nationwide analysis of transvaginal tape release for urinary retention after tension-free vaginal tape procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/52\">",
"      Ennemoser S, Sch&ouml;nfeld M, von Bodungen V, et al. Clinical relevance of occult stress urinary incontinence (OSUI) following vaginal prolapse surgery: long-term follow-up. Int Urogynecol J 2012; 23:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/53\">",
"      Jundt K, Wagner S, von Bodungen V, et al. Occult incontinence in women with pelvic organ prolapse - Does it matter? Eur J Med Res 2010; 15:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/54\">",
"      Richter HE, Albo ME, Zyczynski HM, et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010; 362:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/55\">",
"      Meltomaa S, Backman T, Haarala M. Concomitant vaginal surgery did not affect outcome of the tension-free vaginal tape operation during a prospective 3-year followup study. J Urol 2004; 172:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/56\">",
"      Rafii A, Paoletti X, Haab F, et al. Tension-free vaginal tape and associated procedures: a case control study. Eur Urol 2004; 45:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/57\">",
"      Huang KH, Kung FT, Liang HM, et al. Concomitant pelvic organ prolapse surgery with TVT procedure. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/58\">",
"      Jo YH, Kim K, Rhee JE, et al. The accuracy of emergency medicine and surgical residents in the diagnosis of acute appendicitis. Am J Emerg Med 2010; 28:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/59\">",
"      Bradley CS, Zimmerman MB, Qi Y, Nygaard IE. Natural history of pelvic organ prolapse in postmenopausal women. Obstet Gynecol 2007; 109:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/60\">",
"      Handa VL, Garrett E, Hendrix S, et al. Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women. Am J Obstet Gynecol 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/61\">",
"      Dietz HP. Prolapse worsens with age, doesn't it? Aust N Z J Obstet Gynaecol 2008; 48:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/62\">",
"      Kudish BI, Iglesia CB, Sokol RJ, et al. Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol 2009; 113:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/63\">",
"      Yip SK, Pang MW. Tension-free vaginal tape sling procedure for the treatment of stress urinary incontinence in Hong Kong women with and without pelvic organ prolapse: 1-year outcome study. Hong Kong Med J 2006; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/64\">",
"      Wang KH, Wang KH, Neimark M, Davila GW. Voiding dysfunction following TVT procedure. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/65\">",
"      Ballert, KN, Biggs, G, Isenalumhe, A, Rosenblum N and Nitti VW. Managing the urethra at the time of transvaginal pelvic organ prolapse repair: a urodynamic apprach (abstract). Neurourol Urodyn 2008; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/66\">",
"      Sokol AI, Jelovsek JE, Walters MD, et al. Incidence and predictors of prolonged urinary retention after TVT with and without concurrent prolapse surgery. Am J Obstet Gynecol 2005; 192:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/67\">",
"      Abbasy S, Lowenstein L, Pham T, et al. Urinary retention is uncommon after colpocleisis with concomitant mid-urethral sling. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/68\">",
"      Agarwala N, Hasiak N, Shade M. Graft interposition colpocleisis, perineorrhaphy, and tension-free sling for pelvic organ prolapse and stress urinary incontinence in elderly patients. J Minim Invasive Gynecol 2007; 14:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/32/1546/abstract/69\">",
"      Moore RD, Miklos JR. Colpocleisis and tension-free vaginal tape sling for severe uterine and vaginal prolapse and stress urinary incontinence under local anesthesia. J Am Assoc Gynecol Laparosc 2003; 10:276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8068 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1546=[""].join("\n");
var outline_f1_32_1546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22077833\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptomatic prolapse and incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prolapse with no symptoms of incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incontinence with no symptoms of prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Detecting occult incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Informed consent and patient goals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHOOSING AN ABDOMINAL OR VAGINAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16125469\">",
"      SELECTION OF PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16125477\">",
"      Symptomatic POP and SUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POP with no symptoms of SUI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16125530\">",
"      - Abdominal approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H501610\">",
"      - Vaginal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H502447\">",
"      Concomitant versus staged procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUI with asymptomatic POP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Women at high surgical risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Women planning future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8068|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/3/38964\" title=\"algorithm 1\">",
"      Occult SUI flowchart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8068|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43939\" title=\"figure 1\">",
"      Anatomy occult SUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/30/4591\" title=\"figure 2\">",
"      Voiding diary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43607?source=related_link\">",
"      Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17319?source=related_link\">",
"      Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=related_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32120?source=related_link\">",
"      Urodynamic evaluation of women with incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_32_1547="Steroid compound dose equiv";
var content_f1_32_1547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing equivalents for common steroid compounds",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Steroid compound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose equivalent, mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisolone",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1547=[""].join("\n");
var outline_f1_32_1547=null;
var title_f1_32_1548="Progn ampullary CA";
var content_f1_32_1548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year survival in a series of 1301 patients with ampullary cancer reported to the SEER* registry between 1988 and 2003",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Stage at presentation",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Five-year survival percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       OS",
"      </td>",
"      <td class=\"subtitle2\">",
"       CSS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ia",
"      </td>",
"      <td>",
"       218",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       74",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ib",
"      </td>",
"      <td>",
"       255",
"      </td>",
"      <td>",
"       57",
"      </td>",
"      <td>",
"       66",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIa",
"      </td>",
"      <td>",
"       252",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       41",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIb",
"      </td>",
"      <td>",
"       483",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       34",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       N stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       N0",
"      </td>",
"      <td>",
"       518",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       59",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       N1",
"      </td>",
"      <td>",
"       749",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       28",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OS: overall survival; CSS: cause-specific survival.",
"     <br>",
"      * SEER: Surveillance, Epidemiology and End Results database of the National Cancer Institute.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: O'Connell, et al. Ann Surg Oncol 2008; 15:1820.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1548=[""].join("\n");
var outline_f1_32_1548=null;
var title_f1_32_1549="Late-onset GBS infection rx";
var content_f1_32_1549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous treatment of late-onset group B streptococcal infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site(s) of infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Empirical therapy*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definitive therapy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia without a focus",
"       </td>",
"       <td>",
"        <p>",
"         Ampicillin, nafcillin,&nbsp;or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin or cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         150,000-200,000 units/kg per day divided every 6 hrs",
"        </p>",
"       </td>",
"       <td>",
"        10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"       <td>",
"        <p>",
"         Ampicillin and/or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin or cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         450,000-500,000 units/kg per day divided every 4-6 hrs",
"        </p>",
"       </td>",
"       <td>",
"        14 to 21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellulitis/adenitis",
"       </td>",
"       <td>",
"        <p>",
"         Nafcillin or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin or cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         150,000-200,000 units/kg per day divided every 6 hrs",
"        </p>",
"       </td>",
"       <td>",
"        10 to 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic arthritis",
"       </td>",
"       <td>",
"        <p>",
"         Nafcillin or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         150,000-200,000 units/kg per day divided every 6 hrs",
"        </p>",
"       </td>",
"       <td>",
"        14 to 21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteomyelitis",
"       </td>",
"       <td>",
"        <p>",
"         Nafcillin or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         150,000-200,000 units/kg per day divided every 6 hrs",
"        </p>",
"       </td>",
"       <td>",
"        21 to 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        <p>",
"         Ampicillin, nafcillin,&nbsp;or vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin or cefotaxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin G",
"        </p>",
"        <p>",
"         150,000-200,000 units/kg per day divided every 6 hours",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;10 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GBS: group B streptococcus; CSF: cerebrospinal fluid.",
"     <br>",
"      * Selection will depend on age and presumed source of infection (maternal, hospital or community).",
"      <br>",
"       &bull; Definitive therapy should be started once GBS is identified by culture; clinical improvement is evident; and for meningitis, CSF is sterile at 24-48 hours of therapy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.680.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1549=[""].join("\n");
var outline_f1_32_1549=null;
var title_f1_32_1550="FR for CLL";
var content_f1_32_1550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fludarabine and rituximab (FR) for chronic lymphocytic leukemia",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rituximab",
"        </strong>",
"       </td>",
"       <td>",
"        375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 0.9 percent sodium chloride (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. Subsequent infusions: start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.",
"       </td>",
"       <td>",
"        <p>",
"         Cycle 1: Day 1 and 4",
"        </p>",
"        Cycles 2 through 6: Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fludarabine",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL NS or D5W and administer over 30 minutes.",
"       </td>",
"       <td>",
"        All cycles: Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MINIMAL (&lt;10 percent frequency of emesis). No scheduled antiemetic prophylaxis is indicated. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for tumor lysis syndrome:",
"        </strong>",
"        Due to the significant risk of tumor lysis syndrome during the first cycle, all patients should be well hydrated prior to and during therapy and receive allopurinol 300 mg orally once daily beginning the day prior to the first dose of rituximab and continuing for 14 days",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Tumor lysis syndrome: Prevention and treatment\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The rate of severe (grade 3/4) infection was 20 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . As such, we suggest prophylactic hematopoietic growth factors. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial, antifungal, and antiviral prophylaxis. Refer to UpToDate topics on \"Overview of infectious complications following purine analog therapy\" and \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial fludarabine may be required for renal dysfunction",
"        <sup>",
"         [4]",
"        </sup>",
"        . Dose adjustment is not needed for rituximab. Dose adjustments for liver impairment are not needed for fludarabine and rituximab. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatitis screening:",
"        </strong>",
"        Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for prophylaxis. Refer to UpToDate topic on&nbsp;\"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment and as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess renal and hepatic function prior to each cycle and as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess serum creatinine, potassium, phosphate, calcium, uric acid, and LDH daily during treatment for patients at risk for tumor lysis syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelosuppression:",
"        </strong>",
"        Treatment should be delayed until the ANC is greater than 1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , the platelet count is greater than 80,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , and the hemoglobin is greater than 8 g/dL. Treatment should be delayed until these parameters recover to these values or to within 20 percent of the baseline counts. For grade 3 hematologic toxicity, subsequent doses of fludarabine should be reduced by 25 percent from the original dose. If the patient develops grade 4 toxicity, subsequent doses of fludarabine should be reduced by 50 percent from the original dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; LD: lactate dehydrogenase; ANC: absolute neutrophil count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Byrd JC, et al. Blood 2003; 101:6.",
"      </li>",
"      <li>",
"       Rituxan (rituximab) for injection. US FDA-approved product information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed February 1, 2012).",
"      </li>",
"      <li>",
"       Freifeld AG, et al. Clin Infect Dis 2011; 52:e56.",
"      </li>",
"      <li>",
"       Fludara (fludarabine) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed 2/1/2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1550=[""].join("\n");
var outline_f1_32_1550=null;
var title_f1_32_1551="Bone density with raloxifene";
var content_f1_32_1551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Bone mineral density increases with raloxifene in postmenopausal women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Administration of raloxifene at varying doses (30 mg, black dashed line; 60 mg, green line; 150 mg, blue dotted line) resulted in an increase in bone mineral density compared&nbsp;with placebo (black dotted line) in all sites tested over the two-year follow-up period.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_32_1551=[""].join("\n");
var outline_f1_32_1551=null;
